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ABSTRACT

Ovarian cancer is a leading cause of death among women diagnosed with
cancer. Mortality rate is high because an overwhelming majority of new cases are
diagnosed with late-stage disease when the survival statistics are very poor with an
overall 5-year survival rate of less than 40%. Despite the large burden of disease, the
etiology of ovarian cancer is not well understood. In addition to linkage studies that have
identified highly penetrant cancer susceptibility genes such as BRCA1 and BRCA2, the
emergence of Genome Wide Association Studies (GWAS) in the last decade has
facilitated the identification of common genetic variants with low to moderate
penetrance, termed single nucleotide polymorphisms (SNPs). However, the vast
majority of risk-associated SNPs are found in non-coding regions and their mechanistic
basis underlying susceptibility to cancer remains widely unknown.
Functional analyses are critical in providing insight into the mechanism of action
of these variants. In this study we have implemented bioinformatics methods, in silico
tools, and cell culture models to interrogate functional effects of SNPs that predispose
to cancer. Importantly, we have developed and adopted new techniques that have been
instrumental in our functional studies.
GWAS have identified forty chromosomal loci associated with susceptibility to
ovarian cancer. In this study we present a comprehensive fine mapping and functional
analysis of the 8q24.21 ovarian cancer susceptibility locus to establish biological
vii

mechanisms underlying disease susceptibility. This locus was initially identified in a
previous study, which discovered this region to be association with ovarian cancer. This
follow-up work serves to replicate and confirm the initial findings and, most importantly,
to investigate the biological mechanisms underpinning the association with ovarian
cancer at the 8q24.21 chromosomal region.
The 8q24.21 locus is characterized as a gene desert, which interestingly is also
associated with various cancer types including prostate, colorectal, breast and urinary
bladder cancer. Following the signal of association with fine mapping and functional
assays, we identify eight putative causal SNPs, which reside within two distinct
enhancer elements, displaying allele-specific activity in ovarian cells. Long-range
physical interactions with the promoter region of the MYC oncogene, and to a lesser
extent, the non-coding RNA, PVT1, establish these two genes as the targets of the
enhancer elements containing the putative causal SNPs. We present evidence that the
ATF1 transcription factor binds exclusively to the minor allele of variant rs2165806.
Additionally, we report a comparative analysis testing the cell-type specific activity of
different enhancer regions in breast, prostate, colorectal and ovarian cell lines. In
summary, this work highlights the regulatory landscape at the 8q24.21 locus and
provides a mechanistic basis to understand susceptibility to ovarian cancer in this
region.
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CHAPTER ONE:

BACKGROUND

Ovarian Cancer

Epidemiology
Ovarian cancer is the fifth leading cause of cancer death in women, carrying the
highest mortality rate of all gynecologic malignancies (Siegel et al. (2014)). According to
the American Cancer Society, in the United States every year approximately 22,000
new cases are diagnosed and over 15,000 deaths occur due to ovarian cancer. In terms
of population subgroups, rates are highest among Caucasian women and lowest among
African American women (Siegel et al., 2014). Worldwide, there are estimated to be
roughly 204,000 new cases and 125,000 deaths annually (Sankaranarayanan and
Ferlay, 2006). Incidence rates are highest in developed regions of the world, such as
North America and Western and Northern Europe (Bray et al., 2005; Coleman et al.,
1993; Howe et al., 2006). Incidence of ovarian cancer increases with age and over 80%
of tumors occur after the age of 45 years (SEER Cancer Statistics Review, 19752007)(SF, 2010).
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Signs and Symptoms
Although ovarian cancer is known as the ‘silent killer’, over 80% of patients have
symptoms in the early stages of the disease when the tumor is still confined to the
ovaries (Goff et al., 2000). The main contributing factor in the high mortality rate of
ovarian cancer is the lack of specific symptoms associated with the disease when it is
localized to the ovary and has the best survival statistics (Jelovac and Armstrong,
2011). Most symptoms experienced by women with ovarian cancer are common for
many gastrointestinal, genitourinary and gynecological conditions such as abdominal
discomfort or pain, frequent urination, bloating, and early satiety, which are mild and
nonspecific symptoms that are often disregarded by women (Goff et al., 2000; Goff et
al., 2007). Consequently, diagnosis is usually delayed until more severe symptoms (e.g.
increased pain, weight loss, obstruction of the urinary tract/intestines) become apparent
as the disease progresses to more advanced stages (Jelovac and Armstrong, 2011).
Unfortunately, patients presenting with advanced stages of ovarian cancer have dismal
survival rates.

Pathogenesis and Molecular Heterogeneity
The origin and pathogenesis of ovarian cancer are poorly understood. For years
ovarian cancer was considered and treated as a single disease when in fact that is not
the case. Advances in research and treatment have been impeded by the uncertainty of
the tissue of origin of the serous subtype of ovarian cancer and the remarkable
molecular heterogeneity among the different tumor subtypes.

Aside from ovarian

surface epithelium (OSE) which was traditionally thought to be the precursor tissue for
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epithelial ovarian cancer, there is evidence that the secretory tubal epithelial cells in the
fimbria of fallopian tubes as well as endometriosis contribute to ovarian cancer
pathogenesis (Berns and Bowtell, 2012; Kim et al., 2012; Lee et al., 2007).
Malignant epithelial ovarian cancers, known as ovarian carcinomas, are
categorized into four major histologic subtypes that resemble the normal cells from
which they are derived. These histotypes include serous carcinomas originating from
the epithelial lining of the ovaries or fallopian tubes (70%), endometrioid carcinomas
originating from endometrium cells (10-15%), clear cell carcinomas originating from
vaginal cells (10%) and mucinous carcinomas originating from endocervix cells (3%)
(Bast et al., 2009; Cho and Shih Ie, 2009), which are also thought to derive from
metastasis of gastrointestinal tumors (Lee and Young, 2003).
Serous ovarian carcinomas are predominantly high-grade (90%) accounting for
over 70% of all ovarian cancer deaths and will be the focus of this work (Jemal et al.,
2009; Seidman et al., 2004). The different ovarian histological types differ in terms of
disease development, pathology, genetic alterations, and prognosis (Landen et al.,
2008; Levanon et al., 2008; Shih Ie and Kurman, 2004). Based on these observations,
ovarian cancers are classified into two groups designated as type I and type II (Shih Ie
and Kurman, 2004).
Type I tumors are slow growing and encompass low-grade serous, low-grade
endometrioid, mucinous and clear cell carcinomas (Kurman and Shih Ie, 2008). As a
group, these tumors are genetically stable and are generally characterized by mutations
in KRAS, BRAF, ERBB2, CTNNB1, PTEN and PIK3CA (Cho and Shih Ie, 2009; Obata
et al., 1998; Singer et al., 2003; Teer et al., 2017; Wu et al., 2001). Type I tumors have
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slow progression of disease and are mostly diagnosed in early stages of the disease
(Jemal et al., 2009).
Type II tumors, constituting the majority (75%) of all cases, exhibit very
aggressive histology and consist of high-grade serous, high-grade endometrioid and
undifferentiated carcinomas (Kurman and Shih Ie, 2010; Shih Ie and Kurman, 2004).
Expression profiles of type II tumors cluster separately from type I tumors. Type II
tumors are characterized by mutations in TP53 (~ 80% of tumors), BRCA1/2 (~50% of
tumors), and proteins involved in the DNA homologous recombination repair (HRR)
pathway as well as CCNE1 amplifications but rarely encounter mutations that
characterize type I tumors (Bonome et al., 2005; Cancer Genome Atlas Research,
2011; Kuo et al., 2009; Kurman and Shih Ie, 2010; Press et al., 2008; Teer et al., 2017).
In addition, high-grade serous tumors are also characterized by copy number
aberrations and genomic instability, which is explained by disruption of the DNA
damage repair system (Gorringe et al., 2007). Importantly, type II tumors display very
high proliferative index (positive Ki-67 staining) with extremely aggressive clinical
progression and very poor prognosis (Koonings et al., 1989; Siegel et al., 2014).

Diagnosis and Staging
Surgery plays an important role in ovarian cancer because it is essential in
diagnosing, staging the disease and treating ovarian carcinomas. Although different
noninvasive methods are used to detect ovarian cancer, such as pelvic exams; blood
test for cancer antigen, CA 125; and transvaginal ultrasound, they have poor specificity
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and/or sensitivity, so the ultimate determinant factor for staging of ovarian cancer is
surgery (Jelovac and Armstrong, 2011).
According to the Federation of Gynecology and Obstetrics (FIGO) staging
scheme, stage I ovarian cancer tumors are confined to the ovaries (20% of diagnoses);
stage II tumors spread outside of the ovaries but are confined to the pelvis (5% of
diagnoses); stage III tumors are confined to the abdominal cavity (58% of diagnoses);
and stage IV tumors disseminate to lungs or other distant sites outside of the abdomen
(17% of diagnoses) (Benedet et al., 2000). (Table 1)

Table 1: Ovarian cancer stage distribution and survival rate

Adapted from (Benedet et al., 2000).

It is important to emphasize that low stage (I-II) ovarian tumors are not just
simply confined “earlier” forms of high stage (II-IV) tumors (Kobel et al., 2010). Low
stage disease is usually associated with type I tumors (Seidman et al., 2004), while high
stage disease is predominantly found in type II high grade serous ovarian tumors (>
70% of cases) (Gilks, 2004; Vaughan et al., 2011). Unfortunately, only 25% of high
grade serous ovarian cases are diagnosed at early stages (I, II) of the disease when the
prognosis is promising (Benedet et al., 2000; Seidman et al., 2004).
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Stage II is the least frequently diagnosed stage of ovarian carcinomas; the main
reason being lack of a defined anatomical barrier separating the pelvis from the upper
abdomen (Benedet et al., 2000; Vaughan et al., 2011). High-grade ovarian carcinomas
spread quickly by shedding and circulating tumor cells in the abdominal cavity that
eventually implant onto peritoneal surfaces (Jelovac and Armstrong, 2011). Considering
the extremely aggressive clinical progression of serous ovarian carcinomas, once the
disease disseminates outside of the ovaries into the pelvic cavity it spreads rapidly
throughout the abdomen.
Stage III is the most frequently diagnosed stage of ovarian carcinomas (Benedet
et al., 2000). Unfortunately, most of the patients diagnosed with advanced stage (III, IV)
tumors that have spread to the abdominal cavity and other distant sites will die of
disease (Gilbert et al., 2012). The 5-year survival rate for these patients is less than
40% (Jemal et al., 2009).

Treatment and Prognosis
Prognosis for patients with ovarian cancer depends greatly on the stage of
disease at the time of diagnosis and the volume and pathology of tumor remaining after
the initial cytoreduction or debulking surgery (Bristow et al., 2002; Jelovac and
Armstrong, 2011). Patients diagnosed with stage I ovarian carcinomas are generally
treated with surgery alone without adjuvant therapy and have a 5-year disease-free
survival rate of over 90% (Young et al., 1990). Standard treatment of patients diagnosed
with stage II tumors involves surgery followed by 3 cycles of single agent adjuvant
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chemotherapy (e.g. paclitaxel, carboplatin) resulting in a 5-year disease-free survival
rate of 80% (Bell et al., 2006).
Roughly 75% of cases are diagnosed with advance stage (III-IV) ovarian
carcinomas and are treated with cytoreductive surgery followed by 6 cycles of multi
agent combination chemotherapy (ex. cisplatin or carboplatin in combination with
paclitaxel) (Ozols et al., 2003). The outcome of the treatment for these patients varies
depending on the amount of residual tumor left behind after debulking surgery - the
smallest remaining tumor lesions having the best prognosis (Bristow et al., 2002;
Vaughan et al., 2011). Patients with optimally debulked disease (i.e. residual tumor <
1cm) have a 10-year survival rate of 25% (Benedet et al., 2000). Patients with
suboptimally debulked tumors (i.e. residual tumor > 1cm) have considerably worse
prognosis (Benedet et al., 2000). Nevertheless, a small fraction of stage III patients will
have disease-free survival.
Unfortunately, stage IV patients rarely have long term disease-free survival
(Jelovac and Armstrong, 2011). Despite advances in surgery and chemotherapy, over
90% of women with advanced stage ovarian carcinomas will die after the cancer
relapses (Bukowski et al., 2007). Early detection and prevention are therefore essential
in reducing ovarian cancer mortality (Bast et al., 2009).
PARP inhibitors. Recent developments in identification of targeted approaches
have shown that poly (ADP-ribose) polymerase (PARP) inhibitors lead to improved
survival in patients carrying pathogenic variants in BRCA1 and BRCA2 genes (Fong et
al., 2009; Gien and Mackay, 2010; Gunderson and Moore, 2015; Tangutoori et al.,
2015). Cells rely on two distinct pathways of DNA damage repair in order to maintain
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their DNA integrity. PARP is an enzyme involved in single-strand DNA repair (i.e. nonhomologous end joining; NHEJ), while BRCA 1 and BRCA 2 proteins are involved in
double-strand DNA break repair processes (i.e. homologous recombination; HR)
(Schreiber et al., 2006).
Cells that lose function of BRCA genes have defective double-strand DNA repair
and, therefore, rely heavily on the alternate DNA repair mechanism (i.e. single-strand
DNA repair) which involves PARP (Bryant et al., 2005; Farmer et al., 2005). Because
inactivation of BRCA genes is common in ovarian carcinomas, those patients can
benefit from targeted therapy with PARP inhibitors by impeding the ability of the tumor
cells to repair the chemotherapy-induced DNA damage, causing increased cytotoxicity
of the tumor cells (Ashworth, 2008). Olaparib is a highly potent PARP inhibitor that has
recently been approved by the U.S. Food and Drug Administration (FDA) and the
European Commission for therapy in ovarian cancer patients with high-grade serous
tumors that carry BRCA1 and BRCA2 pathogenic variants and are sensitive to platinum
therapy (Gunderson and Moore, 2015). Treatment with PARP inhibitors has shown
favorable outcomes both for patients with germline and those with somatic ovarian
carcinomas (Carden et al., 2010; Gunderson and Moore, 2015).
.
Protective Factors
Several epidemiologic, lifestyle, environmental and genetic factors are known to
influence a woman’s lifetime risk for ovarian cancer. Factors associated with reduced
risk, such as parity, breastfeeding or lactation, and use of oral contraceptives, have
been hypothesized to confer a protective effect by reducing the number of lifetime
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ovulations (Hankinson et al., 1995; Risch et al., 1994). Specifically, women who have
three children or use oral contraceptives for five years have over 50% reduction of risk
(Whittemore et al., 1992).
One theory is that reducing the number of lifetime ovulations reduces the
damage and inflammation of the ovarian epithelium that occurs with each ovulation
(Auersperg et al., 1997; Ziltener et al., 1993). There is evidence that nonsteroidal antiinflammatory drugs (NSAIDS) and other anti-inflammatory medicines may reduce risk of
developing ovarian cancer (Fairfield et al., 2002).
It has also been hypothesized that both pregnancies and oral contraceptives
provide a protective hormonal environment (e.g. reduced gonadotropin, estrogen levels;
high progestin levels) that decreases risk of developing ovarian cancer by promoting
apoptosis of genetically damaged ovarian epithelial cells that would likely transform into
malignant cells (Risch, 1998; Rodriguez et al., 1998; Salehi et al., 2008). The hormonal
effect may also explain the excess level of protection obtained beyond the effect of
pregnancy and oral contraceptive use in reducing lifetime ovulations (Whittemore et al.,
1992).
A noticeable reduction (20%-50%) in ovarian cancer risk has been observed in
women who have undergone tubal ligation or hysterectomy, thus, removing the tissues
that are thought to be the precursors of ovarian carcinomas in the first place (Hankinson
et al., 1993; Irwin et al., 1991; Loft et al., 1997). Another mechanism of protection
provided by gynecologic procedures is hypothesized to be the disruption of ascending
infections of the ovaries associated with talcum powder and pelvic inflammatory disease
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as well as decrease of blood flow to the ovaries (Chiaffarino et al., 2005; Huncharek et
al., 2003; Risch and Howe, 1995).

Risk Factors
Increased incidence of ovarian cancer has been associated with nulliparity, late
menopause, early menarche, and hormonal therapy, which increase the number of
lifetime ovulations and exposure to estrogen (Morch et al., 2009; Salehi et al., 2008).
Furthermore, endometriosis (an inflammatory disorder) has been associated with
increased risk of ovarian carcinomas (Ness, 2003; Van Gorp et al., 2004). Interestingly,
there is evidence of increased prevalence of ovarian cancer in regions with low sunlight
exposure, suggesting that reduced sunlight and vitamin D levels may increase risk of
developing the disease (Egan, 2006; Lefkowitz and Garland, 1994; Rodriguez, 2003).
Cigarette smoking is also associated with increased risk of certain subtypes of epithelial
ovarian carcinomas (Jordan et al., 2006). Although it is unclear whether physical activity
influences ovarian cancer risk, sedentary behavior is associated with increased risk in
two studies (Patel et al., 2006; Zhang et al., 2004).

The Genetics of Ovarian Cancer. Although multiple factors play a role in
modifying ovarian cancer risk, the strongest impact is observed in association with
genetic factors (Stratton et al., 1998). Ovarian cancer tends to aggregate in families.
Although family studies cannot differentiate whether the aggregation is due to genetic or
environmental causes, studies on monozygotic twins and inbred populations provide
evidence that the observed familial clustering of ovarian cancer is mainly due to genetic
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factors rather than lifestyle or environmental factors (Goldgar et al., 1994; Lichtenstein
et al., 2000).
The relative risk of women who have a first-degree relative affected with ovarian
cancer ranges between three to twelve, increasing with the number of affected relatives
within the family (Stratton et al., 1998). These families commonly carry pathogenic
variants in BRCA1 and BRCA2 genes, which are involved in DNA damage repair
processes, or MLH1 and MSH2 genes, which are part of the mismatch repair (MMR)
system and act to repair nucleotide mismatch errors during DNA replication (Wheeler et
al., 2000). Risk is highest in families that carry BRCA1 or BRCA2 mutations (Antoniou
et al., 2002; Lawrenson et al., 2015b; Pharoah and Ponder, 2002). Mutations in
BRCA1/2 genes have been associated with high grade serous ovarian cancer, while
mutations in MMR genes are more likely associated with mucinous and endometrioid
ovarian carcinomas (Berns and Bowtell, 2012; Fujita et al., 1995; Lawrenson et al.,
2015a).
A portion of ovarian cancers are known to occur as part of two common
hereditary cancer syndromes: the hereditary breast and ovarian cancer syndrome,
involving BRCA1 and BRCA2, and the Lynch syndrome, alternately known as the
hereditary non-polyposis colorectal cancer (HNPCC) syndrome, involving (MMR) genes
such as MLH1, MSH2, MSH6, PMS2, and EPCAM (Lawrenson et al., 2012; Lawrenson
et al., 2015b; Lawrenson et al., 2013; Pharoah and Ponder, 2002; Walsh et al., 2011).
Procedures and regulations for genetic testing for known ovarian cancer susceptibility
genes have already been established in the clinic (Kauff et al., 2008; Lindor et al.,
2006).
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Germline pathogenic variants have also been found in two additional highly
penetrant cancer susceptibility genes, TP53 and PTEN. (Lawrenson et al., 2012;
Lawrenson et al., 2015b). Pathogenic variants in highly penetrant ovarian cancer
susceptibility genes are rare in the population, but have a strong genetic effect and are
therefore highly penetrant, meaning a good proportion of the women carrying the
mutation will develop the disease (Figure 1) (Manolio et al., 2009; Pharoah et al., 2004).
Additional variants with intermediate genetic effect have been identified in
various genes involved in ovarian cancer processes. Some of these genes include
ATM, CHEK1, CHEK2, BRIP1, BARD1, PALB2, RAD50, RAD51C, RAD51D, which are
involved in DNA damage repair and cell cycle processes (Castera et al., 2014; Kuusisto
et al., 2011; Lawrenson et al., 2012; Staples and Goodman, 2013; Thorstenson et al.,
2003; Walsh et al., 2011). Pathogenic variants in moderately penetrant genes are found
in low frequency and have a moderate to intermediate genetic effect in ovarian cancer
risk (Figure 1) (Manolio et al., 2009).
Still, high and moderately penetrant pathogenic alleles of known ovarian cancer
susceptibility genes account for approximately 50% of hereditary cases and only 1015% of all ovarian cancer cases, thus explaining only a fraction of the excess familial
risk, suggesting that other genetic factors are involved in ovarian cancer processes
(Gayther et al., 1999; Lawrenson et al., 2010; Lawrenson et al., 2013; Pharoah et al.,
2004)
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Figure 1. Ovarian cancer susceptibility genes and their contribution to disease.
Examples of different ovarian cancer susceptibility genes are plotted by their
approximate strength of genetic effect versus allele frequency. Rare genes with large
effect size are highly penetrant, common variants with low effect size have low
penetrance, and genes with modest effect size and intermediate allele frequency have
intermediate penetrance of the disease. Adapted from (Manolio et al., 2009).

Since the search for rare, highly-penetrant ovarian cancer susceptibility genes
such as BRCA1 and BRCA 2 has been exhausted, the focus has recently shifted
towards exploring genetic variants that confer moderate to low risk (low-penetrance)
and are common in the population (Pharoah et al., 2004; Pharoah and Ponder, 2002).
Although these variants individually have a small genetic effect, collectively they may
have a significant effect on the disease (Fasching et al., 2009; Pharoah et al., 2004).
Recently, new population-based association studies have identified several loci that are
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associated with ovarian cancer susceptibility (Bolton et al., 2010; Goode et al., 2010;
Kuchenbaecker et al., 2015; Permuth-Wey et al., 2013; Pharoah et al., 2013; Song et
al., 2009). Although these variants have a small genetic effect, they are common in the
population and collectively may explain the remaining genetic contribution to risk of
developing ovarian cancer (Figure 1) (Fasching et al., 2009; Manolio et al., 2009;
Pharoah et al., 2004).

Decreasing Ovarian Cancer Mortality
Several factors contribute to the high mortality rate of ovarian cancer. The
screening modalities currently available are ineffective (Partridge et al., 2009). The
disease symptoms are mild and non-specific and the diagnosis is usually delayed until
disease has progressed extensively. Moreover, the highly heterogeneous and extremely
aggressive histology of ovarian carcinomas present a challenge to clinicians to
successfully treat the disease, resulting in very poor survival rates for ovarian cancer
patients.
Considering the devastating lethality of ovarian carcinomas, it is suggested that
targeting prophylactic measures and improved screening strategies to high-risk women
(i.e. having inherited predisposition and greatest risk of developing the disease) have
significant potential in reducing ovarian cancer mortality (Fasching et al., 2009; Pharoah
and Ponder, 2002). A better understanding of the disease is critical for developing
strategies for risk assessment, prevention, early detection, and development of
therapeutic agents to ultimately improve survival.
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Genome Wide Association Studies (GWAS)

High-penetrance Genes and Linkage Studies
Defective BRCA1 and BRCA2 genes are rare in the population but are highly
penetrant, following to some extent a Mendelian or single-gene pattern of inheritance
(Pharoah et al., 2004). Highly penetrant pathogenic variants and traits are deposited in
a publicly available database named the Online Mendelian Inheritance in Man (OMIM).
Family-based linkage studies have been successful in identifying rare, highly
penetrant genes such as BRCA1 and BRCA2 and many genes associated with true
Mendelian disorders, such as Huntington’s disease and cystic fibrosis. However, in
ovarian cancer, as well as other cancers, the known susceptibility genes such as
BRCA1, BRCA2 and TP53 explain only a fraction of the excess familial risk, implying
that additional genetic factors are also involved in ovarian cancer processes (Pharoah
and Ponder, 2002).

Low-penetrance Alleles and Association Studies
Most cancers, including ovarian cancer, are very complex diseases with
polygenic inheritance, meaning that the inherited risk is due to multiple risk alleles with
low to moderate individual effect, which collectively may have a significant impact on the
disease (Fasching et al., 2009; Pharoah et al., 2004) (Figure 1). Millions of common
genetic variants such as insertions, deletions, sequence repeats or nucleotide
substitutions have been found in the human genome (Cargill et al., 1999; Genomes
Project et al., 2012).
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The most common type of variation is a single nucleotide base substitution or
polymorphism (SNP), which is generally observed in at least 1% of the population and is
described by minor allele frequency (MAF), referring to the allele with the lower
frequency in a reference population (Chung et al., 2010). Tens of millions of SNPs
identified in the human genome have been catalogued in an international public SNP
database, called the dbSNP (www.ncbi.nih.gov/SNP/) (International HapMap, 2003;
International HapMap et al., 2007).

The Principles of GWAS Design
The best model to study SNP variants is a population-based association study,
which compares the frequency of the SNP alleles in disease- or trait-affected individuals
to a comparable control group (Cardon and Bell, 2001; Risch, 2000). A genome-wide
association study (GWAS) is a hypothesis-free approach used to identify SNPs across
the genome that are associated with a trait or disease, such as cancer (Stadler et al.,
2010). By comparing distribution of alleles between cases and controls, GWAS can
identify genomic regions or loci that are associated with the disease (Chung et al., 2010;
Corvin et al., 2010).
GWAS utilize the knowledge that nearby genomic loci are often inherited
together more often than is expected by chance due to lack of recombination, mainly
because of their close juxtaposition to each other (Stadler et al., 2010). The nonrandom
association of alleles in adjacent loci within the same chromosome that are often
correlated together is known as linkage disequilibrium (LD) (Reich et al., 2001) (Figure
2)
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Figure 2. Illustration of linkage disequilibrium. The set of alleles or SNPs that are
inherited together through many generations are in linkage disequilibrium. The LD
fragment is delineated by recombination events that occur during meiosis.

The most commonly used measure of LD in GWAS is the r², which is a statistical
correlation between two loci or SNPs that takes into account the LD as well as the allele
frequency (Pharoah et al., 2004; Visscher et al., 2017). The r² ranges in value from 1
indicating complete correlation or ‘perfect’ LD, which can be disrupted by recombination
events to the point where no correlation is observed, r² = 0 (Orr and Chanock, 2008;
Reich et al., 2001) (Figure 3A).
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Figure 3. LD structure and tagSNP selection. A. LD plot of a chromosome fragment
represented by r2. Color intensity indicates SNPs in increasing LD from r2 = 0 (white), to
r2 = 1 (black). LD structure indicated with red triangle. B. Tagging SNP (green tick) acts
as a proxy for all SNPs within the LD structure (red ticks), but not for the SNPs in the
neighboring regions (black ticks). A tagging SNP that is associated with a trait or
disease represents all SNPs within the LD block as candidate causal SNPs.

The set of alleles or SNPs that are in strong LD and tend to be inherited together
from generation to generation is called a haplotype (Sabeti et al., 2002). LD structures
allow particular SNPs, designated as tagSNPs, to act as surrogates for the other SNPs
on the haplotype (Pharoah et al., 2004) (Figure 3B). The ability of one SNP to act as a
surrogate marker for another is determined both by the strength of LD and their relative
allele frequencies (Pharoah et al., 2004).
The fundamental principle of GWAS testing is to use carefully selected tagSNPs
that serve as proxies for untested SNPs, thus being able to capture genetic diversity
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across the genome (Cardon and Abecasis, 2003; Carlson et al., 2004; Johnson et al.,
2001).

GWAS Methodology and Data Interpretation
The GWAS approach is used to identify common, low-penetrance genetic
variants (e.g. SNPs) associated with a particular disease. Most SNPs that have been
identified by GWAS have a modest effect (OR < 1.3) and relatively high minor allele
frequency (MAF ≥ 1%) so in order to ensure adequate statistical power a large sample
size is required for these studies (Visscher et al., 2017; Wang et al., 2005).
A typical GWAS for cancer susceptibility selects tens of thousands of patients
with a particular cancer (cases) and tens of thousands of individuals without the disease
(controls) from a comparable control group to achieve statistical power for detection of
modest ORs after adjustment for multiple testing. Information on age or ethnicity is
necessary to adjust for 'admixture' confounding(Stadler et al., 2010). Taking into
consideration the requirement for large sample sizes, it is typical for primary GWAS
studies to be grouped together to form meta-analysis, thus enabling discovery of
associations that would otherwise not be evident in separate individual studies (Brisbin
et al., 2011).
In the last thirteen years, the identification of susceptibility loci for common
cancers has been driven by large consortia that are part of the Collaborative
Oncological Gene-environment Study (COGS). These consortia include the Ovarian
Cancer Association Consortium (OCAC), the Breast Cancer Association Consortium
(BCAC), Prostate Cancer Association Group to Investigate Cancer-Associated
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Alterations in the Genome (PRACTICAL), and the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA).
OCAC, created in 2005, is a forum of interdisciplinary investigators conducting
case-control studies of ovarian cancer with the aim of identifying genetic factors related
to the risk of ovarian cancer. Over the years their aim has broadened to include
identification of genetic variation associated with clinical phenotypes such as chemosensitivity and overall survival. Importantly, OCAC is also the only functional venue for
large-scale validation of ovarian cancer susceptibility loci. Since its conception in 2005,
the OCAC has been very successful in identifying genetic loci associated with ovarian
cancer risk (Bolton et al., 2012; Pharoah et al., 2013).
GWAS utilize DNA samples (mainly blood or buccal swabs) from the study
subjects that are genotyped using commercially available microarray chips, which can
perform high-throughput analysis of up a million SNPs at a time. Each DNA sample is
genotyped for a set of tagSNPs that are selected to capture the genomic diversity
across the entire human genome by serving as proxies for untested SNPs (Yang et al.,
2013).
The basic statistical analysis in GWAS is logistic regression with disease status
as the dependent variable and SNP genotype as the independent variable (Corvin et al.,
2010). Logistic regressions are performed for each SNP in the microarray chip (i.e.
about one million regression models per chip), identifying the reference allele for each
SNP along with the odds ratio and p-value (Corvin et al., 2010).
Since multiple tests are performed, stringent statistical thresholds are needed to
avoid false-positive results. The most commonly used adjustment for multiple testing in
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GWAS is the Bonferroni correction in which the standard type I error p = 0.05 is divided
by the number of tests performed (typically one million per chip) thus generating an
acceptable GWAS threshold of p ≤ 5 x 10-8 (Corvin et al., 2010; Stadler et al., 2010). Pvalues that are smaller than expected by chance pass the threshold of significance (i.e.
P ≤ 5 x 10-8) for GWAS and highlight a genomic locus that may be casually associated
with the disease.
The standard for a successful GWAS finding includes (1) a strong association in
the initial sample, (2) replication of association in an independent study, and (3) a
cumulative p-value, p ≤ 5 x 10-8 (Studies et al., 2007). Since its first application in 2005,
the GWAS method has been very successful in identifying genomic loci associated with
different traits and diseases as is evident with over 3,000 publications in the GWAS
catalog of the National Human Genome Research Institute (NHGRI) (Welter et al.,
2014) (A Catalog of Published Genome-Wide Association Studies).

Ovarian Cancer Loci Identified by GWAS
Genome wide association studies to date have identified 40 genomic loci
associated with ovarian cancer risk (Bojesen et al., 2013; Bolton et al., 2010; Chen et
al., 2014; Goode et al., 2010; Kar et al., 2016; Kelemen, 2015; Kuchenbaecker et al.,
2015; Permuth-Wey et al., 2013; Pharoah et al., 2013; Phelan et al., 2017; Shen et al.,
2013; Song et al., 2009). These risk-associated loci are found mainly in noncoding
regions of the DNA (e.g. between genes or within introns) and are associated with small
genetic effect (odds ratio; OR), or low penetrance – meaning, a small frequency of
individuals who carry the SNP variant will manifest the disease.
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Compared to highly-penetrant genes such as BRCA1 and BRCA2 that have
odds ratios greater than 7, the OR for the identified ovarian SNPs, and all SNPs in
general, lie between 0.8 to 1.4 (Kuchenbaecker et al., 2015). This is in line with the
expected small biological effect of SNP variants under the common-disease-common
variant model. Although individually these SNPs have a modest effect, it is
hypothesized that the common occurrence of SNPs in the population and the
cumulative effect of particular SNP sets contribute significantly to the burden of disease
(Pharoah et al., 2004). This observation may be also due to the GWAS association
capturing the actual causal variant that carries most of the effect among the pool of
variants identified.
The 8q24 ovarian cancer locus. A previous study reported the 8q24 locus,
tagged by the SNP (rs10088218) variant allele associated with the protective effect,
especially in the serous subtype (OR = 0.76, 95% CI 0.70-0.81, p = 8 x 10-15) (Goode et
al., 2010). Two additional SNPs, rs1516982 and rs10098821, also reached genome
wide significance (p ≤ 5 x 10-8). This locus is located approximately 800 kb telomeric to
the myelocytomatosis (MYC) proto-oncogene (see Figure 4 for illustration).
The most strongly associated SNP, rs10088218, was also tested for association
with overall survival in patients classified in ovarian cancer subgroups different from
serous (e.g. histological subtype, tumor stage and tumor grade), but no evidence of
association was observed (Goode et al., 2010). Real time PCR analysis of MYC levels
in 48 primary human ovarian surface epithelium cell cultures and 24 ovarian cancer cell
lines revealed significant increase of MYC expression in the ovarian cancer cell lines
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compared to normal cultures (p = 0.0011); however, no evidence of association was
observed between SNP allele and gene expression (Goode et al., 2010).
Architecture of the 8q24 genomic region. The 8q24 locus is a well-known
cancer susceptibility region that is associated with different types of cancer including
prostate, breast, ovarian, bladder, pancreatic, colorectal and lung cancer (Easton et al.,
2007; Eeles et al., 2008; Ghoussaini et al., 2008; Goode et al., 2010; Gudmundsson et
al., 2007; Kiemeney et al., 2008; Low et al., 2010; McKay et al., 2017; Michailidou et al.,
2013; Pharoah et al., 2013; Tenesa et al., 2008; Tomlinson et al., 2007; Yeager et al.,
2007; Zanke et al., 2007; Zhang et al., 2016).
This region is characterized as a gene desert, which by definition is a large
genomic region devoid of protein-coding genes without any apparent relevance in
biological functions (Ovcharenko et al., 2005; Venter et al., 2001). Nevertheless, there is
ample evidence that some gene deserts, including 8q24, contain regulatory sequences
that play an important role in regulating expression of distantly located genes (Huppi et
al., 2012; Jia et al., 2009; Nobrega et al., 2003; Pomerantz et al., 2009).
The only well-annotated gene in the 8q24 region is the myelocytomatosis (MYC)
proto-oncogene, which is a transcription factor known to be involved in many biological
processes that are important in cancer development and progression, including growth
and proliferation, transformation, differentiation, and apoptosis (Adhikary and Eilers,
2005). Other genes in the area include transmembrane protein 75 (TMEM75), which
yields a protein of unknown function, and plasmacytoma variant translocation 1 (PVT1),
producing a long non-coding RNA.
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Many cancer loci are clustered in a region centromeric to MYC at distances
between 30-800 kilobase pairs (kb) away (Figure 4). There are at least 6 distinct cancer
susceptibility loci most of which are specific for a particular cancer (Amundadottir et al.,
2006; Easton et al., 2007; Gudmundsson et al., 2007; Haiman et al., 2007b).
Interestingly, one region contains highly correlated SNPs that are associated with
prostate, colorectal and ovarian cancer suggesting a shared underlying factor that
influences the risk of the three different cancers (Ghoussaini et al., 2008; Haiman et al.,
2007a; Tomlinson et al., 2007).
There is growing evidence suggesting that SNPs present in the various cancer
susceptibility regions at the 8q24 locus reside within regulatory sequences and regulate
transcription of MYC through long range interactions with its promoter region, likely in a
cell type specific manner (Ahmadiyeh et al., 2010; Jia et al., 2009; Pomerantz et al.,
2009; Sotelo et al., 2010; Wright et al., 2010). However, MYC transcript levels have
been difficult to evaluate, mainly due to the inability of the current available platforms to
detect slight changes in expression levels, thus most studies fail to show a correlation
between risk allele and MYC expression levels (Grisanzio and Freedman, 2010; Huppi
et al., 2012).
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Figure 4. Chromosome 8q24 architecture. Genome Browser view of specific SNPs
for various cancer loci identified at the 8q24 chromosomal region that have been
deposited in the Catalog of Published GWAS. Blue highlight indicates association with
prostate cancer; yellow = colon cancer; green = prostate and colon cancer; pink =
breast cancer; red = bladder cancer; grey = lung cancer; purple = pancreatic cancer;
orange = ovarian cancer.

Nevertheless, it has been suggested that even subtle changes in expression
levels can influence tumorigenesis (Yan et al., 2002). An in vivo study by Wasserman et
al. revealed that one of the prostate cancer variants in the 8q24 locus is associated with
endogenous MYC expression during the early development stages of prostate tissue,
suggesting that risk alleles may play a significant role in carcinogenesis well before
tumor formation, in specific and brief time points during the development (Wasserman
et al., 2010).
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Genomic alterations in the 8q24 genomic region. In addition to accumulation
of various cancer-associated SNPs, the 8q24 genomic region is also known to be
subject to a variety of frequent somatic aberrations, including translocations,
rearrangements, viral integration, mutations, and amplifications (Beroukhim et al., 2010;
Dalla-Favera et al., 1982; Patel et al., 2004; Peter et al., 2006).
This region was initially recognized to be the target of various chromosomal
translocations such as t(8:14) and less frequently t(8:22) and t(2:8), which are
characteristic of Burkitt’s Lymphoma, thus positioning the MYC oncogene next to an
active promoter, resulting in increased expression and malignant transformation (DallaFavera et al., 1982; Zech et al., 1976).
Additionally, a large scale study has identified 8q24 as the most frequently
amplified region across many human cancers (Beroukhim et al., 2010; Haverty et al.,
2009).

More

specifically,

The

Cancer

Genome

Atlas

(TCGA)

project

(http://cancergenome.nih.gov/), which has catalogued molecular aberrations in 489 high
grade serous ovarian tumors, has reported that the MYC region is one of the most
commonly amplified in ovarian carcinomas (Cancer Genome Atlas Research, 2011).
The 8q24 region has also been identified as the most common site of human
papilloma virus (HPV) integration in genital neoplasia, accompanied with amplification of
various foci within the 8q24 region (Durst et al., 1987; Herrick et al., 2005; Kraus et al.,
2008; Peter et al., 2006). However, the role of HPV in ovarian carcinogenesis is
inconclusive. There are no reports of coincidence of ovarian cancer and cervical cancer.
There is evidence of high HPV prevalence in ovarian cancer tissue, but it varies widely
by geographical area ranging from 45.6% (95% CI, 31.0-60.3) in Asia, to 18.5% (95%
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CI, 8.5-28.6) in Eastern Europe, to 1.1% (95% CI, -1.6 to 3.8) in Western Europe and
zero in North America (Rosa et al., 2013; Svahn et al., 2014).
Altogether, there is ample evidence pointing at a critical role of the 8q24 region in
cancer processes that warrants further exploration of this genomic region to better
understand the mechanisms underlying susceptibility to ovarian cancer in this locus.

Mechanisms of Transcriptional Regulation

Gene Transcription
The central dogma of molecular biology describes the sequential transfer of
information from the DNA genetic code to RNA to protein (Crick, 1970; Crick, 1958),
although there are exceptions to the rule (Baltimore, 1970; Gerstein et al., 2007). The
process of generating RNA from a DNA template is termed transcription and there is
evidence that up to 75% of the human genome can be transcribed (Djebali et al., 2012).
Eukaryotic cells contain three classes of RNA polymerase enzymes (RNA pol I, II, and
III) which are used to catalyze synthesis of different classes of RNA (Hahn, 2004).

Mechanism of Transcription Initiation and Elongation
Transcription of protein-coding genes into messenger RNA (mRNA) involves the
assembly of the RNA polymerase II (pol II) transcription machinery at the promoter of a
gene (Hahn, 2004). RNA Pol II is an enzyme consisting of twelve subunits that requires
various additional proteins for promoter recognition and transcription initiation (Myer and
Young, 1998; Ptashne and Gann, 1997).
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Promoters contain DNA sequence elements that bind and orient RNA pol II
subunits, specifying the location of transcription for a specific gene (Juven-Gershon et
al., 2008). Core promoters typically contain a TATA element, an (A+T)-rich sequence
located 50-70 bp upstream of the transcription start site (TSS). The TATA element is
recognized and bound by the TATA binding protein (TBP), which is responsible for
recruiting RNA pol II to the TSS (Struhl, 1989).
Additional core promoter elements, such as the initiator element (Inr),
downstream promoter element (DPE), and TFIIB-recognition element (BRE) are
recognized by general transcription factors (GTFs), which assist in assembling the RNA
pol II transcription machinery (Smale and Kadonaga, 2003).
Typically, once transcription initiation starts, the RNA pol II machinery transcribes
a short distance (20-50 bp) and then is paused by physical association with pause
control factors (Adelman and Lis, 2012). The paused polymerase may proceed to
elongation or terminate transcription altogether by releasing the nascent RNA.
Pause release and elongation proceed upon recruitment of transcription
elongation factors, such as the positive elongation transcription factor b (P-TEFb),
through formation of elongation complexes (Luo et al., 2012; Smith et al., 2011).
Transcription factors such as MYC regulate transcriptional pause release of RNA pol II
by interacting with P-TEFb, thus controlling transcription regulation of a target gene by
regulating its transcription elongation (Rahl et al., 2010).
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The Fundamentals of Transcriptional Regulation
Regulation of transcription is essential for all living organisms as it controls many
biological processes, including cell growth, differentiation, response to internal and
external stimuli, development, and disease (Struhl, 1995). The groundwork for the basic
concepts of transcriptional regulation was initiated in bacterial systems over five
decades ago (Jacob and Monod, 1961). Today, it is well-established that transcription
factors binding to specific DNA sequences at regulatory elements are the fundamental
basis of transcriptional regulation, along with their cofactors, the transcription machinery
and various chromatin regulators (Lee and Young, 2013). Regulatory mechanisms that
control the differential and dynamic expression of genetic information define the
properties of cells and delineate individual cell types (Hobert, 2008).
Transcriptional regulation is achieved by combinations of interactions between
regulatory elements (i.e. promoters, enhancers, silencers and insulators) and a wide
variety of molecular factors such as transcription factors, cofactors and chromatin
remodelers (Coulon et al., 2013; Hubner et al., 2013).
Transcriptional regulation requires two interconnected levels of regulation: one
involves transcription factors and the transcription machinery, and the second involves
chromatin organization and its regulators (Lee and Young, 2013).
Transcriptional

regulation

by

transcription

factors

and

enhancers.

Transcription factors typically control gene transcription by binding enhancer elements
and recruiting cofactors and the RNA pol II machinery to target genes (Lelli et al., 2012;
Ong and Corces, 2011; Spitz and Furlong, 2012). The timing, location and the level of
transcription for a specific gene is determined by DNA regulatory sequences, which
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include the core promoter, proximal regions and enhancer regions (Fuda et al., 2009).
The core promoter works in concert with the other regulatory regions to regulate
transcription (Andersson et al., 2015).
Enhancer regions contain regulatory elements called enhancers that guide
recruitment of specific transcription factors, which can be classified as activators or
repressors depending on whether they act to stimulate or inhibit transcription (Fuda et
al., 2009). Activators can facilitate transcription initiation by interacting directly with
many GTFs (e.g. TBP, TFIIA, TFIIB, TFIID), or through recruitment of co-activators,
such as the Mediator (Esnault et al., 2008; Kim et al., 1994). Cofactors play a central
role in DNA loop formation and maintenance between enhancers and promoters, which
is an important genomic structure for proper gene control (Kagey et al., 2010).
Additionally, activators recruit chromatin-modifying enzymes that modulate
chromatin condensation (and, consequently, accessibility of the RNA pol II transcription
machinery to promoters), thus directly affecting gene expression (Henikoff, 2008;
Schulze and Wallrath, 2007). Co-activators often function as histone modifiers (e.g.
histone acetyltransferases (HATs), histone methyltransferases (HMTs), ATP-dependent
chromatin remodelers, or mediators in RNA pol II recruitment (Roeder, 2005).
Transcriptional repressors inhibit transcription by directly or indirectly (i.e. via
recruitment of co-repressors) recruiting chromatin modifying complexes to remodel
chromatin into a condensed or inactive form (Shapiro and Shapiro, 2011). Insulator
proteins are also another class of transcription factors, which identify insulator
nucleotide sequences, that set boundaries between adjacent genes by blocking actions
of cis-regulatory sequences in one gene from interfering with a neighboring gene (Bell
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et al., 1999; Kellum and Schedl, 1991). They are generally 300 bp to 2 kb in length and
have multiple binding sites for large proteins such as CTCF (Bell et al., 2001; BurgessBeusse et al., 2002).
Transcription factor binding sites are the fundamental units of regulatory
sequences (Levo and Segal, 2014). These are short (6-12 bp) DNA sequences, often
called sequence motifs, that have particular specificity for DNA-binding proteins (i.e.
transcription factors), which upon recruitment regulate transcription of associated
genes. Enhancers are important transcription factor binding platforms (generally 200500 bp) that contain multiple recognition sites (i.e. regulatory elements) for various
transcription factors, thus facilitating cooperative binding of multiple transcription factors
to individual enhancers (Panne, 2008).
Enhancers are central players in transcriptional regulation in eukaryotic cells
(Andersson et al., 2015; Levo and Segal, 2014). Enhancers can be located upstream or
downstream from their target gene promoters and are found in proximity as well as over
long genomic distances (up to 1 Mb) from their associated genes (Bondarenko et al.,
2003; Zabidi et al., 2015). Binding of cell-type specific factors to enhancers play a
central role in driving lineage-specific gene expression (Calo and Wysocka, 2013).
Transcription factors bound to enhancers can regulate transcription of nearby or
distantly located genes through physical interactions that

involve chromatin loops

between enhancers and their target genes (Krivega and Dean, 2012). Distant
enhancers are brought to close proximity with their target gene promoter mainly by
means of looping structures and 3D chromatin architecture (Gorkin et al., 2014).
Transcription of most genes requires involvement of several different transcription

31

factors coming together, each binding to its appropriate sequence (i.e. enhancer),
collaborating to activate gene expression by enabling recruitment of the RNA pol II
transcription machinery to the core promoter (Ptashne and Gann, 1997; Struhl, 1995).
Enhancers can be identified by mapping the locations of transcription factor
binding genome wide (Chen et al., 2008). When transcription factors are not known,
certain characteristic features can be used to identify putative enhancer regions such as
sensitivity to DNase treatment and nucleosome modifications (Buecker and Wysocka,
2012; Thurman et al., 2012). Enhancer activity of putative enhancers can be
experimentally tested in luciferase reporter assays (Buckley et al., 2016).
Sequence variations in enhancer regulatory regions may perturb transcription
factor binding and transcriptional regulation of their target genes, thus contributing to
disease. Studies show that a significant portion of genomic variants associated with
common diseases are concentrated in regulatory DNA regions (Maurano et al., 2012).
Interestingly, recent studies have explored the role of transcription factors at
enhancers and the potential impact of enhancer templated non-coding RNAs (eRNAs)
in transcription (Kim et al., 2010; Natoli and Andrau, 2012; Ong and Corces, 2012; Ren,
2010; Spitz and Furlong, 2012). It has been suggested that enhancers are similar to
gene promoters in reference to DNA regulatory units, nucleosome positioning, and
transcription factor binding, as well as functional similarities (i.e. initiate transcription by
RNA pol II), although they operate at a slower rate than true gene promoters (Core et
al., 2014; De Santa et al., 2010; Kim et al., 2010; Koch et al., 2011).
Transcriptional regulation by chromatin organization and chromatin
regulators. In eukaryotic cells, genomic DNA is coiled around nucleosomes, which are
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complexes of four different histone molecules (two H3-H4 and two H2A-H2B) appearing
like ‘beads on a string’ (Felsenfeld and Groudine, 2003; Olins and Olins, 1974). The
nucleosome is the fundamental unit of chromatin that can be further condensed to
generate higher order chromatin (Gerchman and Ramakrishnan, 1987).
The dense packaging of genomic DNA hinders accessibility of promoters and
enhances by RNA pol II and other factors involved in transcription. However,
nucleosomes are controlled by diverse chromatin regulators that can dynamically
remove, displace, or modify nucleosomes, allowing the transcription machinery access
to the regulatory DNA sequences (Cairns, 2007; Hartley and Madhani, 2009;
Shivaswamy et al., 2008; Workman and Kingston, 1992).
Two common histone variants that are used to replace core histones include
H3.3 and H2A.Z (Altaf et al., 2010; Goldberg et al., 2010; Jin et al., 2009). This results
in less stable nucleosomes (i.e. more flexible structure of the genome), thus facilitating
dynamic processes such as DNA transcription, replication and repair (Diesinger and
Heermann, 2009; Hubner et al., 2013; Jin and Felsenfeld, 2007). It is hypothesized that
sites of nucleosomal hypermobility enable accessibility of DNA by transcription factors,
which in turn recruit chromatin remodeling complexes (e.g. SWI/SNF, INO80) resulting
in nucleosomal exclusion from enhancer DNA (Calo and Wysocka, 2013; Li et al.,
2012).

Methods for Studying Chromatin Structure: ChIP-seq and FAIRE-seq
Organization of chromatin structure is an important aspect of transcriptional
regulation in eukaryotic cells (Wallrath et al., 2008). Chromatin that is not bound around
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nucleosomes is accessible by regulatory factors as well as the transcription machinery.
Traditionally, these segments have been detected experimentally through their
increased sensitivity to nuclease digestion, particularly DNase I, which is a biofeature of
regulatory sequences (Gross and Garrard, 1988; Urnov, 2003). Other methods have
been developed to analyze and characterize chromatin structure such as Chromatin
Immunoprecipitation followed by high-throughput sequencing (ChIP-seq), which is a
technique used to identify DNA fragments that are bound by specific proteins, allowing
precise mapping of protein-DNA interactions in vivo throughout the genome (Barski et
al., 2007; Ho et al., 2016; Kellum and Schedl, 1991; Robertson et al., 2007; Zingher,
2003).
On the other hand, Formaldehyde-Assisted Isolation of Regulatory Elements
followed by high-throughput sequencing (FAIRE-seq) is a technique used to isolate
nucleosome-depleted DNA genome-wide (Giresi et al., 2007; Giresi and Lieb, 2009;
Simon et al., 2012; Waki et al., 2011). Genomic regions depleted of nucleosomes
correspond largely to DNase I hypersensitive sites, regulatory elements such as active
promoters, enhancers, silencers and insulators, as well as histone modifications
associated with active transcription (Consortium et al., 2007; Giresi et al., 2007; Kim et
al., 2005a; Kim et al., 2005b; Koch et al., 2007).
Chromosome Conformation Capture (3C) is a technique used to analyze higher
order chromatin and will be discussed in much detail in Chapter 3 of this manuscript
(Dekker et al., 2013; Splinter et al., 2004).
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Higher Chromatin Organization – Topological Domains
The recent development of Chromosome Conformation Capture (3C) and 3Cbased techniques used for genome-wide analysis have provided insight into the longrange interactions and organization of chromatin in vivo (de Wit and de Laat, 2012;
Gibcus and Dekker, 2013; Sanyal et al., 2011). One model of chromatin organization
proposes the folding of chromatin into discrete topological domains, which are
organized into fractional globules and further into chromosome territories, however still
permitting

interaction of distant genomic sites within or between chromosomes

(Bancaud et al., 2012; Lieberman-Aiden et al., 2009).
Topological domains have been found to overlap significantly with cis-regulatory
promoter-enhancer units in the mouse genome (Shen et al., 2012). The interchromosomal interactions for transcription regulation are not well-understood yet;
however, it has been hypothesized that many genes are found in the periphery of the
chromosomal territories co-localizing in interchromatin granules or transcription factories
(Brown et al., 2008; Hu et al., 2008; Schoenfelder et al., 2010). These factories are
aggregates of RNA pol II complexes with multiple regulatory sequences that
synergistically increase transcriptional activity by accumulation of transcription factors
needed for transcription (Edelman and Fraser, 2012).

Post-translational Modifications
Chromatin organization and transcription is greatly regulated by post-translational
modifications of the histone components in the nucleosome (Heintzman et al., 2009).
These modifications do not affect the nucleosome core, instead they alter the N-terminal

35

tails of the core histones by covalent attachment of different chemical groups (SantosRosa and Caldas, 2005). Chemical modifications include methylation, acetylation,
phosphorylation, ubiquitination and sumoylation (Lee and Young, 2013).
Methylation of lysine 4 residue on histone H3 (H3K4me1) was one of the first
histone modifications identified to be associated with distal enhancer regions, while tri
methylation of the same residue (H3K4me3) was associated with active promoters and
was found specifically at the 5’ end of annotated genes (Heintzman et al., 2007).
Acetylation of lysine 27 on histone H3 (H3K27ac) is enriched in regions containing
active enhancers and promoters and is associated with transcriptional activity
(Creyghton et al., 2010; Wang et al., 2008). The various histone modifications have a
functional impact on regulating transcription of specific genomic regions (Guttman et al.,
2009).
ENCODE. The ENCyclopedia Of DNA Elements (ENCODE) Project is a
collaborative effort of many research groups worldwide that aimed to create a
comprehensive catalogue of functional elements in the human genome (Consortium,
2004). The ENCODE project has produced a genome-wide chromatin landscape of the
human genome based on mapping of genomic regions associated with transcription,
transcription factor binding, histone modification and chromatin structure, thus enabling
the profiling of regulatory elements and other functional domains in various cell types
(Consortium, 2012).
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Transcriptional Dysregulation in Disease
Our ability to better understand regulatory sequences is critical in refining our
understanding of essential biological processes. Genetic variation in enhancer
sequences may influence disease mainly through dysregulation of gene expression
(Lee and Young, 2013).
Recent evidence emerging from GWAS indicates that a significant portion of
disease-associated SNPs are found in regulatory DNA sequences and have been
associated with many human diseases, including cancer (Ahmadiyeh et al., 2010;
Bojesen et al., 2013; Bolton et al., 2010; Ghoussaini et al., 2008), Alzheimer’s disease
(Gaj et al., 2012), cardiovascular disease (Harismendy et al., 2011; Zhao et al., 2012),
inflammatory lung disease (Han et al., 2012), and multiple sclerosis (Alcina et al., 2013).
Alteration of regulatory sequences frequently underlie development of diseases as is
evident in cancer, where many molecular and biological changes that are characteristic
of disease are associated with changes in regulatory regions (Maurano et al., 2012;
Sakabe et al., 2012; Sur et al., 2013).
Many disease-associated SNPs have cell type specific effects and are
associated with disease in a specific cell type (Ernst et al., 2011). Enhancers operate in
a cell-type specific manner and can explain how genetic variants such as SNPs
contribute to tissue specific disease phenotypes (Maurano et al., 2012).
Mutations in transcription factors have also been known to promote
tumorigenesis. As an example, MYC is one of the most frequently mutated genes found
in human and animal cancers and overexpression of this transcription factor is
associated with aggressive pathology and poor clinical outcomes (Cole, 1986;
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Henriksson and Luscher, 1996; Marcu et al., 1992). Many tumor cells rely on the
transcription factor MYC for their growth and proliferation (Littlewood et al., 2012). In
tumor cells with overexpressed MYC, the transcription factor accumulates in the
promoter regions of its target genes and recruits the P-TEFb elongation factor,
producing increased levels of transcripts, known as transcriptional amplification (Lin et
al., 2012; Nie et al., 2012).
In addition, alterations in co-activator complexes that interact with multiple
transcription factors and facilitate DNA looping can contribute to carcinogenesis and
other diseases. For instance, mutations in the Mediator coactivator complex has been
found in various tumors, particularly in uterine leiomyomas and leiosarcomas and
prostate cancer (Barbieri et al., 2012; Makinen et al., 2011).
Dysregulation of chromatin remodelers and epigenetic control are critical
contributors to cancer pathogenesis. Loss-of-function mutations in genes coding for
nucleosome remodeling proteins such as the SWI/SNF complex proteins and ARID1A
have been associated with various cancer types, suggesting that defects in mobilizing
nucleosomes are involved in cancer processes (Hargreaves and Crabtree, 2011; Tsai
and Baylin, 2011; Wilson and Roberts, 2011).
Further research is needed to advance our understanding of transcriptional
regulatory circuits that incorporate information about regulatory sequences and key
molecular factors working together at regulatory sites to control gene transcription.
Knowledge of sequence variation that contributes to disease is important in
understanding mechanisms of disease, which can lead to improved diagnostic and
therapeutic approaches to disease.
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CHAPTER TWO:

IDENTIFYING FUNCTIONAL SNPS

Note to reader:
Parts of this section have been published in Buckley & Gjyshi et al. 2016 (Nat
Protoc. 2016 Jan;11(1):46-60). These articles are Open Access and, when cited, can be
reproduced for non-commercial use.
A second manuscript (Gjyshi et al.) has also been submitted for review and
includes portions of this chapter.

Introduction
To investigate the mechanism by which SNP allele variation contribute to ovarian
cancer pathogenesis, we performed a comprehensive functional analysis of the 8q24.21
ovarian cancer susceptibility locus. The most highly associated SNP (rs10088218) that
tagged this region to be associated with epithelial ovarian cancer (EOC) was reported in
a previous study, where the effect allele [A] was associated with decreased risk of
ovarian cancer, especially in the high grade serous subtype (OR = 0.76; 95% CI 0.700.81; p = 8 x 10-15) (Goode et al., 2010). Two additional SNPs (rs1516982 and
rs10098821, r2 with rs10088218 = 0.64 and 0.80, respectively) also reached genome
wide significance (p ≤ 5 x 10-8). These SNPs map to a gene desert region that is devoid
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of protein-coding DNA, located approximately 800 kb telomeric to the proto-oncogene
MYC, a well-known transcription factor that is involved in many cancer processes
including growth and proliferation, differentiation, transformation and apoptosis
(Adhikary and Eilers, 2005).
Interestingly, the 8q24 chromosomal region is also associated with other types of
cancers including prostate, breast, colorectal and bladder cancers (Easton et al., 2007;
Eeles et al., 2008; Ghoussaini et al., 2008; Kiemeney et al., 2008; Tenesa et al., 2008;
Thomas et al., 2008; Tomlinson et al., 2007; Yeager et al., 2007). These loci are located
centromeric to MYC at distances between 30 kb to 800 kb. Growing evidence indicates
that these loci contain transcription regulatory regions that influence MYC expression
(Ahmadiyeh et al., 2010; Jia et al., 2009; Pomerantz et al., 2009; Sotelo et al., 2010;
Wright et al., 2010).
In this study, we performed fine mapping of the 8q24.21 ovarian susceptibility
locus followed by detailed functional analysis using progressively stringent criteria to
select variants that contribute functionally and are most likely to drive association with
risk. Considering that all the SNPs are located in non-coding regions, we hypothesized
that these SNPs function within enhancer elements that modify transcriptional regulation
of a gene involved in ovarian cancer pathogenesis (Freedman et al., 2011; Monteiro
and Freedman, 2013). We developed a new method called Enhancer Scanning
(Buckley et al., 2016) and also employed various methods to select functional SNPs
with allele-specific effects on their respective enhancer elements and target genes,
testing in OSE and fallopian tube epithelial (FTE) cells since both cell types may
represent the cell of origin for high grade serous ovarian cancer.
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Results

Fine Mapping Analysis and Identification of Candidate Functional SNPs

Note to reader: This part of the analyses was performed by Paul Pharoah and
Jonathan Tyrer as part of COGS.

Genotyped data from four genotyping projects were used for the analyses: the
COGS project and three genome-wide association studies (see methods). A dense set
of fine-mapping SNPs spanning 2.06 Mb were selected for genotyping in COGS to
cover the association for ovarian, breast and prostate cancer. Additional coverage was
provided by imputation into a reference panel from the 1000 Genomes Project.
Overall, 43 studies from 11 countries provided data on 15,437 women diagnosed
with invasive EOC, 9,627 of whom were diagnosed with serous EOC, and 30,845
controls from the general population.

The final data set for analysis comprised

genotypes for 14,043 SNPs of which 2,418 had been genotyped for the COGS samples.
Genotype calls of genotyped and imputed SNPs were then tested for association with
ovarian cancer (see methods).
The strongest association was for the genotyped SNP, rs1400482, with the major
allele [G] being associated with an increased risk (OR = 1.18, 95% CI 1.13 – 1.23; p =
2.5x10-13). The association was even stronger for serous ovarian cancer (OR = 1.29,
95% CI 1.22 – 1.36; p = 1.9 x10-20) so subsequent analyses were restricted to this
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subtype. The relative risk for high-grade serous (OR = 1.27, 95% CI 1.19 – 1.35) was
slightly smaller than that for low-grade serous (OR = 1.51, 95% CI 1.21 – 1.88) and low
malignant potential serous tumors (OR = 1.53, 95% CI 1.30 – 1.80), a difference that
was of borderline significance (p = 0.050). The regional association plot for serous
ovarian cancer is shown in Figure 5A. The current study did not investigate association
with survival. However, the initial study that identified the 8q24 locus for association with
ovarian cancer reports no evidence of association of the tag SNP (rs10088218) with
overall survival in all ovarian cancer cases or the serous subgroup (Goode et al., 2010).

42

Figure 5. Fine mapping analysis delineates a 31 kb region of association with
ovarian cancer in the 8q24.21 locus. A. Genotyped (red) and imputed (black) SNPs
plotted by their position on chromosome 8 (x-axis) and –Log10(p values) of association
to ovarian cancer for the serous subtype (y-axis). The dashed black horizontal line
represents the threshold for odds 100:1 for causal variant. Dashed red vertical lines
represent the most highly associated SNPs delineating a 31 kb region. SNPs in blue are
associated with the indicated traits in the GWAS catalog (p ≤ 1 X 10-8). PrC, prostate
cancer; CLL, chronic lymphocytic leukemia; HLy, Hodgkin’s lymphoma; BrC, breast
cancer; CrC, colorectal cancer; BlC, bladder cancer; RCC, renal cell carcinoma, Celiac
disease; RA, rheumatoid arthritis; Crohn’s disease; OF, orofacial cleft; Glioma. Note:
The fine mapping analysis and figure were generated by Paul Pharoah. B. Regulatory
landscape of the fine mapped 95 kb region. Tracks are indicated on the right. Ovarian
SNP set contains 52 SNPs with odds 100:1 or better of being the true causal variant
underlying this signal. HindIII sites were used to generate 3C fragments (purple). Tiles
(blue) for enhancer scanning analysis were designed to cover regulatory biofeatures
(FAIRE-seq, H3K27Ac, H3K4Me1) containing candidate functional SNPs (highlighted in
gray).
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Based on the log likelihood statistics from the association analyses there were 52
SNPs with odds of 100:1 or better of being the true causal variant underlying this signal
(Table 2). These included rs10088218 reported by the original GWAS (Goode et al.,
2010). This set of SNPs narrows the association signal down from a ~500kb region to a
~31kb

region

(chr8:129,540,464-129,571,140,

Human

Genome

Browser

hg19

assembly).
Table 2. Candidate functional SNP set
1

SNP ID

rs1400482
rs10088218
rs7814937
rs7010594
rs7010880
rs73374998
rs73374987
rs28399026
rs73376904
rs73375000
rs77247401
*rs10108517
*rs13328411
rs10089868
rs10089972
*rs17807628
rs10678821
rs6982716
rs6982966
rs1516971
rs10098765
rs1400483
*rs6651252
*rs1516974
rs16903080
rs16903078
rs7839493
*rs10088755
*rs10095481

Chr

8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8

Position (hg19)

100:1 Odds

129541931
129543949
129541475
129542834
129542869
129561323
129557952
129544408
129564944
129561866
129561216
129549562
129551089
129562430
129562458
129551311
129560728
129557592
129557523
129542100
129559311
129547537
129567181
129548134
129546865
129546735
129546651
129551633
129549582

1
1.262379
1.294664
1.367521
1.368137
1.402351
1.590266
1.838685
1.974172
1.985561
2.055666
2.081732
2.177986
2.187478
2.192189
2.197346
2.233789
2.41996
2.457394
2.495778
2.516322
2.667526
2.856799
2.90766
2.931012
2.939388
2.947629
3.148106
3.153455

2

EAF

3

0.132749
0.132693
0.132526
0.132757
0.132765
0.132693
0.134054
0.132877
0.133806
0.133886
0.134051
0.13331
0.133301
0.133965
0.133964
0.133301
0.134144
0.134228
0.134183
0.133784
0.134067
0.133306
0.133746
0.13334
0.133267
0.133259
0.133247
0.133334
0.133346

R²_iCOGS

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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Table 2 (Continued). Candidate functional SNP set
1

Chr

*rs1516976
*rs10113762
rs1400484
*rs1516975
*rs16903081
*rs938650
*rs6651253
*rs938648
rs57593539
rs16903097
*rs938649
*rs13328404
*rs201242438
rs6470637
*rs1561925
*rs2392944
*rs2011527
*rs10103637
*rs10103640
*rs938651
rs28455755
*rs2165806
rs16903065

8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8

SNP ID

Position (hg19)

100:1 Odds

129548258
129552202
129547636
129548193
129548309
129552540
129567292
129552491
129567515
129556356
129552534
129552456
129552855
129556163
129569033
129552856
129555532
129553697
129553703
129555443
129571140
129569551
129540464

3.164988
3.422089
3.433046
3.572978
3.640781
3.690645
4.040629
4.236547
4.281485
4.327115
4.3754
4.546244
4.585047
4.80016
5.379514
5.80866
6.095788
6.104329
6.577806
6.751749
7.248904
7.30311
8.631336

2

EAF

3

0.133343
0.133345
0.133312
0.133327
0.132963
0.133305
0.133752
0.133352
0.133569
0.134047
0.133281
0.133339
0.137634
0.134122
0.132855
0.132756
0.134128
0.134207
0.134195
0.134143
0.132516
0.132827
0.132642

R²_iCOGS

1
1
1
1
1
0.999
1
1
1
1
0.999
1
0.975
1
1
0.875
1
1
1
1
0.979
1
1

1

Asterisk (*) and bold font indicate the 24 SNPs that overlap with ovarian biofeatures.
SNPs with 100 to 1 odds or better of being the causal variant determined by log
likelihood statistics by comparing the likelihood of each SNP from the association
analysis with the likelihood of the most strongly associated SNP (rs1400482).
3
EAF: effect allele frequency
2

The association analyses was repeated for each SNP adjusting for rs1400482 in
order to identify additional, independent signals in the region at p < 10-5. Two further
independent signals were identified (Figure 6): rs74559819 (RAF = 0.037; ORadj = 1.26,
95%CI 1.15 – 1.38; p = 4.4 x 10-7) and rs4524749 (RAF = 0.68; ORadj = 1.09, 95%CI
1.05 – 1.13; p = 7.9 x 10-5). These are uncorrelated (absolute correlation < 0.02) with
the top hit rs1400482 and with each other. Rs74559819 is located within the PVT1
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spanning region and lies in a DNAse I hypersensitive cluster (in 125 cells from
ENCODE) and H3K4me1 region in OSE cells. However the absence of H3K27Ac marks
suggests that it is not an active enhancer (Figure 6A). Rs4524749 is located proximal to
the MYC promoter (Figure 6B).

FAIRE

H3K27Ac

H3K4Me1
K562 ATF1 Std

PVT1

DNase Clusters
Master DNaseI HS
Common SNPs (142)

FAIRE

H3K27Ac

H3K4Me1
K562 ATF1 Std

MYC
MYC
PVT1

DNase Clusters
Master DNaseI HS
Common SNPs (142)

Figure 6. Independent signals revealed by conditional analysis. Chromatin
landscape of SNPs with independent signals in the region at P < 10-5. A. rs74559819
(RAF = 0.037; ORadj = 1.26, 95%CI 1.15 – 1.38; p = 4.4 x 10-7). B. rs4524749 (RAF =
0.68; ORadj = 1.09, 95%CI 1.05 – 1.13; p = 7.9 x 10-5). SNP location is indicated with
blue vertical line. Note: Conditional analysis was performed by Jonathan Tyrer and Paul
Pharoah.
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The association of genotyped and imputed SNPs in the region with the clear cell
and endometrioid subtypes of epithelial ovarian cancer was also evaluated. There was
little evidence for association with endometrioid ovarian cancer. There was a single
SNP, rs2165805, that achieved genome-wide significance for association with clear cell
ovarian cancer (Figure 7: OR = 1.46, 95% CI 1.28 – 1.66; p = 8.2 x 10-9). This SNP was
not correlated with the nearby SNPs associated with serous ovarian cancer and
represents an independent association signal for the region. Additionally, the clear cell
SNP is not located in a region with any specific chromatin features.

K562 ATF1 Std

Figure 7. Independent signals revealed by histological subtype analysis.
rs2165805 is associated with clear cell ovarian cancer (OR = 1.46, 95% CI 1.28 – 1.66;
p = 8.2 x 10-9). SNP location is indicated with blue vertical line. Note: Subtype analysis
was performed by Jonathan Tyrer and Paul Pharoah.
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Mapping SNPs to Enhancer Elements
The 52 candidate causal SNPs for serous OC risk are all located in non-protein
coding regions. We evaluated the overlap between these SNPs and regions displaying
features of active regulatory elements using Formaldehyde Assisted Isolation of
Regulatory Elements followed by sequencing (FAIRE-seq; indicative of open
chromatin), and histone modifications H3K27Ac and H3K4Me1 in a panel of ovarian
normal and cancer cell lines (Coetzee et al., 2015). This analysis identified four regions
(Figure 5B; labeled E1-E4) in which 24 candidate causal SNPs overlap with recognized
chromatin features in immortalized normal ovarian surface epithelial (iOSE4, iOSE11)
(Lawrenson et al., 2009) and fallopian tube surface epithelial cells (iFTSEC33,
iFTSEC246) (Coetzee et al., 2015) (Figure 5B &Table 2). Very few differences are
observed in the overlapping of SNPs with regulatory biofeatures in ovarian versus
fallopian tube cells, with no apparent segregation of SNPs according to cell type, giving
no indication whether one of these cell types is most likely involved in ovarian cancer
compared to the other.

Functional Analysis of SNPs

Identifying Functional SNPs by Enhancer Scanning
To validate the predicted enhancer regions in ovarian cells, a reporter assay was used
to scan the four regions for enhancer activity (Buckley et al., 2016; Pharoah et al.,
2013). First, seven genomic tiles were generated (Figure 5B; blue boxes) and cloned in
forward and reverse orientations upstream of a basal SV40 promoter driving luciferase
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expression. Each construct was transfected into iOSE4cMYC ovarian cells (Tertimmortalized and partially transformed with MYC) (Lawrenson et al., 2009) and
luciferase levels were measured 24 h post transfection. Four tiles (T3, T4, T6, and T7),
in regions E2, E3 and E4 containing a total of 15 candidate functional SNPs, displayed
significant enhancer activity in at least one orientation (Figure 8).

Figure 8. Enhancer scanning in iOSE4cMYC ovarian cells. Box and whisker plots of
luciferase activity for tiles in forward (A) and reverse (B) orientation containing the
reference allele for each SNP. * denotes significant (unpaired t-test; p ≤ 0.05)
differences in relation to the control (empty vector).

Identifying Functional SNPs with Allele-Specific Enhancer Activity
To assess the effect of both alleles for each of the 15 SNPs, first we generated tiles
containing the minor allele for each SNP by using site-directed mutagenesis. The
enhancer activity of tiles containing the major versus the minor allele was tested in a
similar set up as the enhancer scanning assay. Eleven candidate functional SNPs
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displayed significant differences between major and minor allele (unpaired t-test; p ≤
0.05) (Figure 9) (Table 3).

A

B

Figure 9. Allele-specific activity in iOSE4cMYC ovarian cells. Box and whisker plots of
luciferase activity for tiles that were tested for allele-specific activity in forward (A) and
reverse (B) orientation. * denotes significant (unpaired t-test; p ≤ 0.05) differences in
relation to the reference allele. Boxes separate SNPs according to the tiles they are
located in for comparison with the effect of the reference allele in their respective tiles.
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Table 3. Proposed functional SNPs at the 8q24.21 locus
Region

SNP

Major
a
Allele FWD

E1

rs13328411

T

A

0.0889

84.8

E1

rs17807628

T

C

0.0895

E1

rs10088755

G

A

E2

rs10113762

T

rs13328404

E3

E4

Minor
Allele

MAF

b

2

Serous Χ

Enhancer
Scanning

c

EMSA

3C

+

−

−

84.8

+

+

−

0.1124

83.9

−

−

−

C

0.1122

83.5

+

+

+

A

G

0.1120

83.2

+

+

+

rs938648

T

G

0.1118

83.4

+

+

+

rs938649

G

T

0.1098

83.2

+

+

+

rs938650

G

A

0.1120

83.3

+

+

+

rs201242438

C

del

NA

?

+

+

+

rs2392944*

C

T

0.1713

62.7

+

−

+

rs6651252

T

C

0.1524

83.9

−

−

+

rs6651253

G

C

0.1522

84.0

−

−

+

rs1561925*

C

T

0.1508

82.7

+

+

+

rs1561924*

G

A

0.1508

83.5

−

+

+

rs2165806*

G

C

0.1516

82.1

+

+

+

d

(a) All SNP alleles are shown in forward human genome orientation. SNPs marked with
(*) are originally described in reverse in dbSNP. Throughout the paper we refer to SNP
alleles using their forward orientation. (b) MAF, minor allele frequency; (c) EMSA,
electrophoretic mobility shift assay; (d) 3C, chromosome conformation capture,
indicates whether the 3C probe that contains the SNP was found to interact with target
gene promoters.

Identifying SNPs with Allele-Specific Binding of Nuclear Proteins by EMSA
To further investigate allele-specific effects, we performed Electrophoretic
Mobility Shift Assays (EMSA) to investigate differential binding of nuclear proteins of
major versus minor allele for each of the 15 SNPs. We used nuclear extracts of
iOSE4cMYC ovarian cells incubated with DNA probes containing either major or minor
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allele for each SNP. Ten SNPs exhibited differential binding of nuclear proteins between
the reference and effect allele (Table 3) (Figure 10). Altogether, we identified nine SNPs
in regions E1, E2, and E4 that displayed reproducible allele-specific activity in both
assays (enhancer scanning and EMSA). Taken together with the fine mapping data
these results indicate that these nine SNPs are the most likely candidate causal SNPs
at this locus (Table 3).

Figure 10. Protein binding profiles of candidate functional SNPs at 8q24.21 by
EMSA in iOSE4cMYC cells. Assays were performed in technical duplicates (run in two
lanes) with probes containing either the reference or effect allele for SNPs within tiles
with enhancer activity. Underlining indicates SNPs with allele-specific binding of nuclear
proteins in both technical duplicates and in two independent experiments.

Network of Distant Enhancers at the 8q24 Locus
In order to determine the cell type specificity of different enhancer regions in the
8q24 locus that have been associated with various cancers, we generated tiles for the
enhancer scanning assay containing SNPs associated with prostate (Prostate region 1;
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rs4242382), breast (rs13281615), and colorectal (rs6983267) cancer risk, with previous
data for functional interaction with MYC (Ahmadiyeh et al., 2010; Pomerantz et al.,
2009; Sotelo et al., 2010; Wright et al., 2010). We also included ovarian SNPs identified
in this study (tiles 3, 4, 6, and 7 covering regions E2-4) (Figure 11A). Tiles were
generated for each cancer locus and enhancer activities were tested in iOSE4cMYC
(ovarian), Cal51 (breast), HCT116 (colorectal), and LNCaP (prostate) cell lines for
comparison (Figure 11B).
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A

B

Figure 11. 8q24 region including different cancer susceptibility loci. A. Six linkage
disequilibrium blocks are highlighted indicating the location of association to Prostate
(regions 1 and 2 (Pr1 and Pr2), Breast (Br), Colorectal (Col), urinary bladder (Ub), and
Ovarian (Ov) cancer risk. Genomic tiles (pink) containing the three SNPs (red) that were
tested in luciferase assay have been shown to have functional activity in previous
studies (Ahmadiyeh et al., 2010; Pomerantz et al., 2009; Sotelo et al., 2010; Wright et
al., 2010). B. Summary of enhancer activity by transfection in iOSE4cMYC. Check mark
indicates enhancer activity.

Excepting ovarian tiles 3 and 4 (Region E2) all tiles displayed enhancer activity in
all three cell lines (Figure 11B and Figure 12). Ovarian tile 3 was negative in Cal51
breast cells and LNCaP prostate cells. Ovarian tile 4 was negative in Cal51 breast cells,
but positive in the other three cancer cell lines. Interestingly, regions defined by SNPs
associated with colorectal, breast, and prostate do not present a chromatin
environment, as judging by presence of FAIRE-Seq, H3K4me1 and H3K27Ac marks in
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ovarian cells. Taken together, these results indicate that different tissues express
factors required to activate these enhancer regions and suggest that tissue specificity is
conferred by the cell type specific chromatin microenvironment, which dictates the
accessibility of the underlying DNA containing the regulatory sequence by the
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Summary
In this chapter, we started from fine mapping analysis of the 8q24.21 ovarian
cancer susceptibility locus, which identified a 95 kb region

of association

(chr8:129,474,065-129,569,064, Human Genome Browser hg19 assembly) (Figure 5).
Additional statistical analyses identified 52 SNPs with odds of 100:1 or better of being
the candidate functional SNP (Table 1 and Figure 5A), narrowing down the signal of
association to a ~32 kb region. Considering that all these SNPs fall in non-coding
regions, we hypothesized that these SNPs exert their functions through enhancer
elements, regulating transcription of distant target genes that are involved in ovarian
cancer pathogenesis.
To test this hypothesis, we identified 24 SNPs, residing within four distinct
enhancer regions (E1-E4, Figure 5B and Table 3), spanning approximately 11 kb. Tiles
designed to cover the predicted enhancer regions, containing 24 SNPs, were tested for
enhancer activity in our enhancer scanning assay, which identified four tiles that
displayed enhancer activity in ovarian cells (Tile 3, 4, 6 & 7, Figure 5B). These tiles
contained 15 candidate causal SNPs that are most likely implicated in ovarian cancer
processes. Luciferase reporter assays and EMSAs were performed to investigate the
allele-specific activity of each of those SNPs, narrowing down the number of candidate
causal SNPs to 9 variants that displayed allele-specific activity in both assays (Table 3).
Furthermore, we also tested the tissue specificity of various enhancer
regions that have been associated with colorectal, breast, and prostate cancer by
designing tiles (Figure 11A) to test in the reporter assay along with the four active
ovarian tiles we identified in enhancer scanning. All tiles were tested in all four cancer
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cell lines (Figure 11 and 12). With the exception of ovarian tiles 3 and 4 (Region E2), all
tiles displayed enhancer activity in all three cell lines (Figure 11B and Figure 12) despite
the lack regulatory biofeatures of the other cancer types in ovarian cells. This shows
that different tissues express factors required to activate these enhancer regions.Tissue
specificity is conferred by the pool of available TFs that are present in the cell as well as
the specific chromatin microenvironment (i.e. epigenetic modifications), which controls
the accessibility of the regulatory DNA sequences by the appropriate transcription
factors.

Materials and Methods

Note to reader: The first two parts in this section have been analyzed by Paul
Pharoah and Jonathan Tyrer as part of COGS.

Fine Mapping and SNP Selection
Fine-mapping of the region was carried out as part of the Collaborative Oncology
Gene-Environment Study (COGS) with the aims of identifying the SNPs most likely to
mediate the causal associations at the 8q24 locus harboring multiple association signals
for breast, ovarian and prostate cancer and to identify novel association signals within
the same region. The association signals that had been reported at the time the finemapping SNPs were selected were: rs10088218 for ovarian cancer, rs13281615,
rs13262406 and rs1562430 for breast cancer; rs12543663, rs10086908, rs1016343,
rs13252298, rs6983561, rs620861, rs6983267, rs10090154, rs16901979, rs13254738
and rs7000448 for prostate cancer.
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All SNPs within a 2.06 Mb interval at 8q24.21 (chr8: 127630906 -129693334)
were identified from the 1000 Genomes Project (1000G) CEU (April 2010) (Genomes
Project et al., 2010) and Hapmap III (International HapMap, 2003). Only variants with
the minor allele called at least twice in the 1000GP data and with an Illumina Design
score > 0.8 were included. All variants correlated with the tagging SNPs (r² > 0.1) were
selected for genotyping. Additional tagging SNPs (r² > 0.9) were selected to capture the
remaining SNPs in the region. Genotyping was done using a customized Illumina
iSelect genotyping array (iCOGS) designed for the Collaborative Oncology GeneEnvironment Study.
The iCOGS array was used to genotype cases and controls from 43 constituent
studies of OCAC, as previously described (Pharoah et al., 2013). Two thousand four
hundred and eighteen SNPs across the 8q24 region were successfully genotyped. In
addition to the OCAC iCOGS data, genotype data were used from previously conducted
ovarian cancer genome-wide association studies. We excluded samples if they were
not of European ancestry, if they had a genotyping call rate of <95%, if they showed low
or high heterozygosity, if they were not female or had ambiguous sex or if they were
duplicates (cryptic or intended). One individual was excluded from each pair of samples
found to be first-degree relatives, and duplicate samples between the iCOGS stage and
any of the GWAS were excluded from the iCOGS data. SNPs were excluded if they
were mono-morphic, had a call rate of < 95%, showed evidence of deviation from
Hardy-Weinberg equilibrium or had low concordance between duplicate pairs. For the
GWAS, we also excluded rare SNPs (MAF < 1% or allele count < 5, respectively). The
final data set comprised genotype data for 11,069 cases and 21,722 controls from
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COGS (‘OCAC-iCOGS’), 2,165 cases and 2,564 controls from a GWAS from North
America (‘US GWAS’) (Permuth-Wey et al., 2011), 1,762 cases and 6,118 controls from
a UK-based GWAS (‘UK GWAS’) (Song et al., 2009), and 441 cases and 441 controls
from the Mayo Clinic. All subjects included in this analysis provided written informed
consent as well as data and blood samples under ethically approved protocols. Overall,
studies from 11 countries provided data on 15,437 women diagnosed with invasive
EOC, 9,627 of whom were diagnosed with serous EOC, and 30,845 controls.
In order to improve coverage we imputed genotype data for SNPs that had not
been genotyped. We performed imputation separately for the iCOGS samples and
each of the GWAS. We imputed variants from 1000 Genomes Project data using the v3
April 2012 release (Genomes Project et al., 2010) as the reference panel using the
IMPUTE2 software (Howie et al., 2009) without pre-phasing. We changed some of the
default parameters in the imputation procedure in order to increase imputation
accuracy. These included an increase in the MCMC iterations to 90 (out of which the
first 15 were used as burn-in), an increase in the buffer region to 500 kb and an
increase in the number of haplotypes used as templates when phasing observed
genotypes to 100. SNPs were included for analysis if the minor allele frequency was
greater than 1% and the imputation r2 greater than 0.3. The final data set comprised
genotypes for 8,022 SNPs of which 2,342 had been genotyped for the COGS samples.

Association Analysis
We evaluated the association between genotype and disease using logistic
regression analyses for each SNP.

The analysis was adjusted for study and for
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population substructure by including the eigenvectors of the first five ancestry-specific
principal components as covariates. We used the same approach to evaluate SNP
associations with serous ovarian cancer after excluding all cases with any other or
unknown tumor subtype. For imputed SNPs, we used expected dosages in the logistic
regression model to estimate SNP effect sizes and P values. We carried out analyses
separately for OCAC-iCOGS samples and the three GWAS and pooled data thereafter
using a fixed-effects meta-analysis. All results are based on the combined data from
iCOGS and the three GWAS. In order to identify a set of potentially causal variants, we
excluded SNPs with a likelihood of being causal of less than 1:100, by comparing the
likelihood of each SNP from the association analysis with the likelihood of the most
strongly associated SNP (rs1400482).

We used custom written software for the

analysis.

Genome Browser
The Genome Browser (https://genome.ucsc.edu/) is a publically available
database developed and maintained by the University of California Santa Cruz (UCSC)
that contains the reference sequence of the human genome and also provides portals
to the ENCODE data. For the in silico analysis we utilized the GRCh37/hg19 human
assembly available in this database. A personal session was created containing the
region of interest on chromosome 8q24. Datasets for ovarian biofeatures including
ChiP-Seq for H3K4me1 and H3K27ac, as well as FAIRE-seq were made available on
the Genome Browser by the Coetzee laboratory (Coetzee et al., 2015). Custom tracks
were generated for the candidate SNP set, enhancer scanning tiles, as well as the
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expected 3C fragments (used in Chapter 3). An example of a bed file used to generate
a custom track for the tiles used in the enhancer analysis is shown in Table 4. A bed file
contains information about the chromosome of interest, genome browser position that
will be displayed on the browser window, name and description for the custom track
with an option to add color specification in RGB format, as well as SNP/tile coordinates
and names included in each custom track.

Table 4. Example of a bed file used to generate a custom track for enhancer tiles
browser position chr8:129,471,565-129,571,564
track name="Tiles" description="Amplicons for enhancer analysis"
visibility=2 color=32,91,229
chr8
129547233 129549217 1
chr8
129549146 129551041 2
chr8
129550538 129551890 3
chr8
129551871 129553687 4
chr8
129553668 129555687 5
chr8
129566784 129567658 6
chr8
129568495 129569898 7

Bed files were uploaded to the genome browser by clicking on the following tabs:
1) manage custom tracks, 2) add custom tracks, 3) chose file, 4) submit. The custom
tracks are added to the genome browser window along with all the other default tracks,
thus enabling us to visualize overlapping features.

Cell Lines
Association analysis identified the most significant SNP, rs1400482, which had a
stronger association when the analysis was restricted to high-grade EOC tumors;
therefore, the subsequent analyses were restricted to this subtype. Based on the
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hypothesis that serous EOC may originate both from ovarian surface and fallopian tube
epithelial cells, we used cell lines and datasets that were derived from these cell types.
Experiments for the functional analyses (reporter assays and EMSAs) were
conducted in normal epithelial ovarian cell line immortalized with human telomerase
(hTERT) and partially transformed with MYC (iOSE4cMYC) as a model for human serous
EOC (Lawrenson et al., 2009; Lawrenson et al., 2010). Experiments for the chromatin
conformation capture (3C) assay (see Chapter 3) were conducted in normal ovarian
surface epithelial cells (iOSE11) and hTERT- immortalized normal fallopian tube surface
epithelial cells (iFTSEC283) (Lawrenson et al., 2009; Lawrenson et al., 2010). Cells
were cultured in a base medium composed of MCDB105 and Medium 199 (SigmaAldrich) at a 1:1 ratio, supplemented with 15% Fetal Bovine Serum (FBS) (SigmaAldrich), 34 µg/mL Bovine Pituitary Extract (BPE) (Thermo-Fisher Scientific), 10 ng/mL
Epidermal Growth Factor (EGF) (Thermo-Fisher Scientific), 5 µg/mL insulin, and 0.5
µg/mL hydrocortisone (Sigma-Aldrich) to make the complete growth medium. The
iOSE4cMYC cells were cultured in complete growth medium containing 2 µg/mL
Blasticidin (Thermo-Fisher Scientific).
Datasets for ovarian

biofeatures,

including FAIRE-Seq,

H3K4me1

and

H3K27ac27 (Coetzee et al., 2015), contain two immortalized normal ovarian surface
epithelial cell lines (iOSE4 and iOSE11), two immortalized normal fallopian tube surface
epithelial cells (iFTSEC33 and iFTSEC246), and two ovarian cancer cell lines, CaOV3
exhibiting molecular profiling characteristic of high-grade serous carcinoma (Domcke et
al., 2013), and UWB1.289, which is a BRCA1-null cell line (DelloRusso et al., 2007).
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Reporter assays for the network analysis of distant enhancers were conducted in
iOSE4cMYC cells described above, as well as in HCT116, a colorectal carcinoma cell
line; Cal51, a breast cancer cell line; and LNCaP, a prostate carcinoma cell line, all of
which were obtained from ATCC and were cultured according to manufacturer’s
specifications.

Enhancer Scanning
Genomic tiles were PCR amplified from genomic DNA obtained from iOSE4cMYC
cells using primers containing att B recombination sites (Table 5). PCR amplification
was performed with HotStar Taq polymerase (Qiagen) followed by gel purification
(Qiagen). Gateway cloning technology (Gateway BP Clonase II from Life Tech) was
used to clone the PCR amplicons into pDONR 221. Inserts were screened by restriction
digest. LR reactions (Gateway LR Clonase II from Life Tech) were used to clone the
genomic tiles in forward and reverse orientation upstream of the SV40 promoter driving
firefly luciferase expression in the pGL3-Promoter-LR vector (Promega) which was
obtained through the Gateway Vector Conversion System (Life Tech). For the reporter
assay, we used iOSE4cMYC cells plated at 5 x 10³ per well in 96-well plates. pGL3
vectors containing individual tiles were co-transfected with the pRL-CMV vector serving
as internal control using Fugene HD (Promega) at a 3:1 ratio of Fugene HD (volume in
ul) to DNA (ng).
For the network analysis of the distant enhancers at the 8q24 locus, Cal 51,
LNCaP and HCT 116 cells were plated at 1 x 104 per well in 96-well plates. pGL3
vectors containing individual tiles were co-transfected with the pRL-CMV vector using
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Lipofectamine 3000 (Life Tech) at a 2:1 ratio of Lipofectamine 3000 (volume in ul) to
DNA (ng).
Luciferase readings were obtained 24 h post transfection using the Dual-Glo
Luciferase Assay System (Promega). Luciferase activity was calculated by normalizing
against the internal control and level of significance was determined by comparing
against luciferase activity in the empty vector (unpaired t test; p value ≤ 0.05).

Table 5. Primers for enhancer analysis
Primer Name

Sequence (5’ to 3’)

Tile 1 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTCACGGCTATGAAGAAATACC

Tile 1 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGCATGCAAAGGTGCTGTATTA

Tile 2 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTGTTCACCTGAACCATGACTT

Tile 2 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGATGGGAAGGGAATAAGATGT

Tile 3 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTCCAGTTTCATGCAGCTTTCA

Tile 3 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGTAAGTGTGGAAGGTGGTGCA

Tile 4 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTTGCACCACCTTCCACACTTA

Tile 4 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGGAGCACATTGCAGTTGGAAA

Tile 5 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTTTTCCAACTGCAATGTGCTC

Tile 5 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGAAAACAGCTGGGAGGAAGGT

Tile 6 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTTATGCCTCGGTTTCCTCATC

Tile 6 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGCCCAGGTAGAGGGAATAGCC

Tile 7 F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTCCTGCTGTATGCCGAGTTTT

Tile 7 R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGTGTCCTGAGAGTGGAGGCTT

BrRs1328165F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTAACCGGTCTTTTCAGTTTATGG

BrRs1328165R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGTTCACCATCCTTGTCCTTGG

ColRs6983267F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTAGACACCAAGAGGGAGGTATCA

ColRs6983267R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGTTACAGCCTGCTGGGAAAGT

Pr1Rs4242385F

GGGGACAAGTTTGTACAAAAAAGCAGGCTACGCGTCAGTCACATCCCACCCAACT

Pr1Rs4242385R

GGGGACCACTTTGTACAAGAAAGCTGGGCTCGAGACCAGTCCTGTCCTGTCTCC
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Site-Directed Mutagenesis
To test the allele-specific activity of SNPs with the reporter assay, we used sitedirected mutagenesis to switch the SNPs from major to minor allele. This was achieved
using the QuickChange XL Site-Directed Mutagenesis kit (Agilent), following the
manufacturer’s protocol. Primers were designed utilizing the freely accessible
QuickChange

Primer

Design

(http://www.genomics.agilent.com/primerDesignProgram.jsp)

Program
available

in

the

manufacturer’s website (Table 6). Vectors containing tile 3, 4, 6 and 7 in reverse
orientation were used as templates to generate the minor alleles for their respective
SNPs. Luciferase activity was measured as described in the Enhancer

Scanning

method described above. The allele specific activity of each SNP was compared against
the template vector containing the major SNP allele(s) in corresponding tile (unpaired t
test; p value ≤ 0.05).
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Table 6. Primers for site-directed mutagenesis
Tile

SNP
rs13328411

45

rs17807628
rs10088755
rs10113762
rs13328404
rs938648

46

rs938649
rs938650
rs201242438
rs2392944*
rs6651252

59
rs6651253
rs1561925*
61

rs1561924*
rs2165806*

Primer Name

Strand Primer Sequence
ttggtgagcctcttgactgactgagttgaaggaat

45-1rs13328411t-a Rev
45-1rs13328411t-a Fwd

+

45-2rs17807628t-c Fwd

+

45-3rs10088755g-a Rev
45-3rs10088755g-a Fwd
46rs10113762t-c Fwd

+
+

46rs10113762t-c Rev
46rs13328404a-g Fwd

catcagtgtgggctaatttgctactggaaatctaagggaaa
gtatgtgtcaataaacagttctttattgtctacataattcatttttttcccagaatt
aattctgggaaaaaaatgaattatgtagacaataaagaactgtttattgacacatac
aaaggccccagcggttgccttagataatacaaacac
gtgtttgtattatctaaggcaaccgctggggccttt

+

46rs13328404a-g Rev
46rs938648t-g Fwd

attccttcaactcagtcagtcaagaggctcaccaa
tttcccttagatttccagtagcaaattagcccacactgatg

45-2rs17807628t-c Rev

agtgtgtagcacacaacaaatagcaaatatcagctgggttttttc
gaaaaaacccagctgatatttgctatttgttgtgtgctacacact

+

ggttttttcccctctccttcagcattaaatgctatagctttca

46rs938648t-g Rev

tgaaagctatagcatttaatgctgaaggagaggggaaaaaacc

46rs938649g-t Rev

agtatagaaagaatctagggaaattatattaagttaaaagaatgaaagctaagcattta

46rs938649g-t Fwd
46rs938650g-a Fwd

+
+

46rs938650g-a Rev
46-6rs201242438del Fwd

+
+

taggaggaaaagtgggccctttgaaatgtgagcag

-

aggataaaaagccagaacttactttggtggcgcc

59-2rs6651253g-c Rev
61rs1561925c-t Fwd

-

gtaccttgcacaagtaataatcactaccattgatctggc
gccagatcaatggtagtgattattacttgtgcaaggtac

61rs1561924g-a Rev

actttggacagcatgaacgtcagtgaagtttatctgg

61rs2165806g-c Rev
61rs2165806g-c Fwd

gcctgaaacctggaagcgaaaagtccttgactg
cagtcaaggacttttcgcttccaggtttcaggc
ggcgccaccaaagtaagttctggctttttatcct

61rs1561925c-t Rev
61rs1561924g-a Fwd

aaattacaaagtagaacctctttttttttttttttttacatttttttgagaaaagagattactaggc
gcctagtaatctcttttctcaaaaaaatgtaaaaaaaaaaaaaaaaagaggttctactttgtaattt
ctgctcacatttcaaagggcccacttttcctccta

59-1rs6651252t-c Rev
59-2rs6651253g-c Fwd

gaacgttgaaaattacaaagtagaacctcttt-tttttttttttttacatttttttgagaaaagag
ctcttttctcaaaaaaatgtaaaaaaaaaaaaa-aaagaggttctactttgtaattttcaacgttc

-

46-7rs2392944c-t Rev
59-1rs6651252t-c Fwd

tcattcttttaacttaatataattgccctaaattctttctatacttaaaaaaatggaagtg
cacttccatttttttaagtatagaaagaatttagggcaattatattaagttaaaagaatga

+

46-6rs201242438del Rev
46-7rs2392944c-t Fwd

taaatgctatagctttcattcttttaacttaatataatttccctagattcttctatact

-

ccagataaacttcactgacgttcatgctgtccaaagt

Primer sequences listed are represented in the 5’ to 3’ direction.

Electrophoretic Mobility Shift Assay
Extraction of nuclear proteins from iOSE4cMYC cells was performed in absence of
detergents as they can interfere with the binding activity of the isolated proteins. We
prepared Dignam based nuclear extracts (Dignam et al., 1983). Briefly, nuclear extracts
were prepared using a hypotonic lysis buffer (10mM HEPES pH 7.9, 1.5mM MgCl 2,
10mM KCl, supplemented with DTT and protease inhibitors) followed by cell disruption
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with a syringe (gauge No. 27) and isolation of the nuclear fraction with an Extraction
Buffer (20mM HEPES pH 7.9, 1.5mM MgCl2, 0.42M NaCl, 0.2mM EDTA, 25% v/v
glycerol, supplemented with DTT and protease inhibitors). The DNA probes were
designed to contain either the reference or effect allele for each SNP positioned
between 20 oligonucleotides on each side (Table 7).

Table 7. DNA probes used in EMSA
SNP

Probe Name

Sequence (5’ to 3’)

rs13328411

rs13328411m F

GGAATTCCTTCAACTCAGTCAGTCAAGAGGCTCACCAATCC

rs13328411M F

GGAATTCCTTCAACTCAGTCTGTCAAGAGGCTCACCAATCC

rs13328411m R

GGATTGGTGAGCCTCTTGACTGACTGAGTTGAAGGAATTCC

rs13328411M R

GGATTGGTGAGCCTCTTGACAGACTGAGTTGAAGGAATTCC

rs17807628m F

CATCAGTGTGGGCTAATTTGCTACTGGAAATCTAAGGGAAA

rs17807628M F

CATCAGTGTGGGCTAATTTGTTACTGGAAATCTAAGGGAAA

rs17807628m R

TTTCCCTTAGATTTCCAGTAGCAAATTAGCCCACACTGATG

rs17807628M R

TTTCCCTTAGATTTCCAGTAACAAATTAGCCCACACTGATG
GAAAAAAATGAATTATGTAGACAATAAAGAACTGTTTATTG

rs17807628

rs10088755

rs10088755m F
rs10088755M F
rs10088755m R
rs10088755M R

GAAAAAAATGAATTATGTAGGCAATAAAGAACTGTTTATTG
CAATAAACAGTTCTTTATTGTCTACATAATTCATTTTTTTC

rs10113762m F

CAATAAACAGTTCTTTATTGCCTACATAATTCATTTTTTTC
GGCAAAGGCCCCAGCGGTTGCCTTAGATAATACAAACACAA

rs10113762M F

GGCAAAGGCCCCAGCGGTTGTCTTAGATAATACAAACACAA

rs10113762m R

TTGTGTTTGTATTATCTAAGGCAACCGCTGGGGCCTTTGCC

rs10113762M R

TTGTGTTTGTATTATCTAAGACAACCGCTGGGGCCTTTGCC

rs13328404m F

TGTGTAGCACACAACAAATAGCAAATATCAGCTGGGTTTTT

rs13328404M F

TGTGTAGCACACAACAAATAACAAATATCAGCTGGGTTTTT

rs13328404m R

AAAAACCCAGCTGATATTTGCTATTTGTTGTGTGCTACACA

rs13328404M R

AAAAACCCAGCTGATATTTGTTATTTGTTGTGTGCTACACA

rs938648m F

GTTTTTTCCCCTCTCCTTCAGCATTAAATGCTATAGCTTTC

rs938648M F

GTTTTTTCCCCTCTCCTTCATCATTAAATGCTATAGCTTTC

rs938648m R

GAAAGCTATAGCATTTAATGCTGAAGGAGAGGGGAAAAAAC

rs938648M R

GAAAGCTATAGCATTTAATGATGAAGGAGAGGGGAAAAAAC

rs938649 &

rs938649/50m F

TCTTTTAACTTAATATAATTTCCCTAAATTCTTTCTATACTTAAAAA

rs938650

rs938649/50M F

TCTTTTAACTTAATATAATTGCCCTAGATTCTTTCTATACTTAAAAA

rs938649/50m R

TTTTTAAGTATAGAAAGAATTTAGGGAAATTATATTAAGTTAAAAGA

rs938649/50M R

TTTTTAAGTATAGAAAGAATCTAGGGCAATTATATTAAGTTAAAAGA

rs10113762

rs13328404

rs938648
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Table 7 (Continued). DNA probes used in EMSA
SNP
rs201242438

rs2392944

rs6651252

rs6651253

rs57593539

rs1561925

rs1561924

rs2165806

Sequence (5’ to 3’)
rs201242438m F TTACAAAGTAGAACCTCTTTTTTTTTTTTTTTTACATTTT
rs201242438M F TTACAAAGTAGAACCTCTTTCTTTTTTTTTTTTTACATTTT
rs201242438m R AAAATGTAAAAAAAAAAAAAAAAGAGGTTCTACTTTGTAA
Probe Name

rs201242438M R

AAAATGTAAAAAAAAAAAAAGAAAGAGGTTCTACTTTGTAA

rs2392944m F

AAAATGTAAAAAAAAAAAAAAAAAGAGGTTCTACTTTGTAA

rs2392944M F

AAAATGTAAAAAAAAAAAAAGAAAGAGGTTCTACTTTGTAA

rs2392944m R

TTACAAAGTAGAACCTCTTTTTTTTTTTTTTTTTACATTTT

rs2392944M R

TTACAAAGTAGAACCTCTTTCTTTTTTTTTTTTTACATTTT

rs6651252m F

ACATAGGAGGAAAAGTGGGCCCTTTGAAATGTGAGCAGAGC

rs6651252M F

ACATAGGAGGAAAAGTGGGCTCTTTGAAATGTGAGCAGAGC

rs6651252m R

GCTCTGCTCACATTTCAAAGGGCCCACTTTTCCTCCTATGT

rs6651252M R

GCTCTGCTCACATTTCAAAGAGCCCACTTTTCCTCCTATGT

rs6651253m F

TGGAGCCTGAAACCTGGAAGCGAAAAGTCCTTGACTGGAGT

rs6651253M F

TGGAGCCTGAAACCTGGAAGGGAAAAGTCCTTGACTGGAGT

rs6651253m R

ACTCCAGTCAAGGACTTTTCGCTTCCAGGTTTCAGGCTCCA

rs6651253M R

ACTCCAGTCAAGGACTTTTCCCTTCCAGGTTTCAGGCTCCA

rs57593539m F

AGGAGCATTTTGAGCTTGCCAACAGGCTCTCCCATGGATTC

rs57593539M F

AGGAGCATTTTGAGCTTGCCGACAGGCTCTCCCATGGATTC

rs57593539m R

GAATCCATGGGAGAGCCTGTTGGCAAGCTCAAAATGCTCCT

rs57593539M R
rs1561925m F

GAATCCATGGGAGAGCCTGTCGGCAAGCTCAAAATGCTCCT
TCTGCAGGCGCCACCAAAGTAAGTTCTGGCTTTTTATCCTC

rs1561925M F

TCTGCAGGCGCCACCAAAGTGAGTTCTGGCTTTTTATCCTC

rs1561925m R

GAGGATAAAAAGCCAGAACTTACTTTGGTGGCGCCTGCAGA

rs1561925M R

GAGGATAAAAAGCCAGAACTCACTTTGGTGGCGCCTGCAGA

rs1561924m F

AGGAGGTGCCAGATCAATGGTAGTGATTATTACTTGTGCAA

rs1561924M F

AGGAGGTGCCAGATCAATGGCAGTGATTATTACTTGTGCAA

rs1561924m R

TTGCACAAGTAATAATCACTACCATTGATCTGGCACCTCCT

rs1561924M R

TTGCACAAGTAATAATCACTGCCATTGATCTGGCACCTCCT

rs2165806m F

TGACTTTGGACAGCATGAACGTCAGTGAAGTTTATCTGGAA

rs2165806M F

TGACTTTGGACAGCATGAACCTCAGTGAAGTTTATCTGGAA

rs2165806m R

TTCCAGATAAACTTCACTGACGTTCATGCTGTCCAAAGTCA

rs2165806M R

TTCCAGATAAACTTCACTGAGGTTCATGCTGTCCAAAGTCA
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Forward and reverse probe pairs were first annealed (10μM each), followed by
labeling with ATP [γ-32P] (Perkin Elmer) using T4 polynucleotide kinase (NEB) and then
cleanup by utilizing the QIAquick Nucleotide Removal Kit (Qiagen). The clean, labeled
probes were subsequently incubated with the previously isolated nuclear protein
extracts using LightShift Poly(dI-dC) (Thermo-Fisher Scientific) in a binding buffer
solution (10mM Tris, 50mM KCl, 1mM DTT, pH 7.4). The reactions were subjected to
electrophoresis on a 6% polyacrylamide gel at 83V, overnight, at 4°C. Gels were dried
and films exposed for 5-24 h. EMSA were performed in at least two independent
experiments (biological replicates) and each probe was run in duplicate (technical
replicates) in each gel. Changes in banding patterns were assessed by visual inspection
and only SNPs in probes showing reproducible changes (present in all biological and
technical replicates) are further analyzed.
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CHAPTER THREE:

IDENTIFYING CANDIDATE TARGET GENES

Note to reader:
A manuscript (Gjyshi et al.) currently under review includes portions of this
chapter.

Introduction
Since the 9 candidate causal SNPs are located in three enhancer regions, we
hypothesize that they exert their functions through the control of a target gene. Thus,
the next step in the analysis is to identify target gene(s) regulated by the three enhancer
regions. The candidate causal SNPs are found in a gene desert region in chromosome
8q24 that is devoid of coding DNA. The only well annotated gene in the area is the MYC
proto-oncogene, located approximately 800 kb centromeric to the region of association
that we are investigating. The initial study that identified this locus for association with
ovarian cancer reported significant increase of MYC expression levels in 24 ovarian
cancer cell lines compared to 48 normal primary human surface epithelium cell cultures
(p = 0.0011); however, no evidence of association was observed between SNP allele of
the tag SNP and gene expression (Goode et al., 2010).
In this chapter, we perform in silico annotation of putative target genes followed
with experimental approaches to identify genes that are active in our panel of ovarian
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cancer and normal cells and are the targets of the enhancer regions we identified in the
previous chapter.

Results

Identification of Candidate Target Genes, MYC and PVT1
We confined our search for promoters of candidate target genes to a 1 Mb span
on each side of the 31 kb region of association specified in the previous chapter,
totaling a span of 2.03 Mb (Figure 13A). This distance was determined based on the
observation that most interactions between enhancers and target genes are found
within 1 Mb of each other (Jin et al., 2013). To identify candidate target genes we used
the University of California Santa Cruz (UCSC) Genes prediction track in the Genome
Browser. The only protein coding genes in this region are the MYC proto-oncogene,
located approximately 800 kb away, and Transmembrane Protein 75 (TMEM75) coding
for a protein of unknown function, located over 600 kb away, both centromeric to the
ovarian cancer susceptibility region. The 2.03 Mb span also includes eight long noncoding RNAs and five micro RNAs (Figure 13A).
We inspected the region and identified promoters located near the transcription
start site (TSS), marked by H3K4me3 histone modifications as indicated in the
ENCODE Regulation track (Consortium, 2012). Next, we examined which of these
genes/transcripts were expressed in ovarian cells using H3K27ac histone modifications
as markers of active promoters, and RNA-seq data in ovarian cells. This analysis
suggested that MYC and PVT1 were actively expressed in ovarian cells (Figure 13B).
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A
Ovarian SNP Set

B

Figure 13. Target genes in the 8q24 locus. A. Region surrounding the fine mapped
region showing all the UCSC genes found within this region. Location of ovarian SNP
set (odds 100:1 or better) (black box) is indicated with an arrow. B. Region containing
the MYC and PVT1 genes showing location of chromatin features (FAIRE-seq and
H3K27AC) for ovarian cells, and RNA-seq data (for iOSE11, iOSE19, iFTSEC33,
iFTSEC237, and iFTSEC246). Note: RNA-seq data were generated by Kate
Lawrenson.

Both have been implicated in ovarian cancer (Guan et al., 2007; Karst et al., 2011;
Lawrenson et al., 2011) and are frequently amplified in 135 (44%) of 311 patients/cases
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(TCGA Provisional, Ovarian Cystadenocarcinoma). Consequently, we tested whether
MYC or PVT1 interacted with enhancer regions in the locus.

Enhancer Regions Display Physical Interactions with Promoters of MYC
and PVT1
We utilized Chromosome Conformation Capture (3C) to investigate physical
interactions between the promoter of candidate target genes, MYC and PVT1, and four
enhancer regions containing the set of 15 candidate SNPs (Regions E1-E4). In our
analyses of iFTSEC283 and iOSE11 cells, the chromatin fragment containing the MYC
promoter shows increased interaction frequencies with regions E2, E3, and E4,
compared to other surrounding fragments in the 8q24 ovarian cancer susceptibility
locus which is located approximately 800 kb away (Figure 14). These regions contain
eight SNPs with allele-specific activity in both functional assays (enhancer scanning
assay and EMSA) (Table 3). The PVT1 promoter region also displays peaks of
interaction with regions E3 and E4, but at a lower frequency compared to the MYC
interactions (Figure 15). These data suggest that promoters of both of these genes
physically interact with enhancer regions identified in the 8q24.21 ovarian cancer
susceptibility locus and are most likely their targets of transcriptional regulation.
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A
iFTSEC283

B

Figure 14. Chromosome conformation capture (3C) analysis of enhancer regions
with MYC at the 8q24.21 locus. Graphs display 3C interactions in iFTSEC283 (A) and
in iOSE11 (B) cells. The bait is anchored at the MYC promoter region (red) which is
tested for physical interaction with 3C fragments (purple bars) containing enhancer
regions (highlighted in gray). 3C interaction with a fragment adjacent to MYC is used as
a reference.
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A

iFTSEC283

B

Figure 15. Chromosome conformation capture (3C) analysis of enhancer regions
with PVT1 at the 8q24.21 locus. Graphs display 3C interactions in iFTSEC283 (A)
and in iOSE11 (B) cells. The bait is anchored at the PVT1 promoter region (red) which
is tested for physical interaction with 3C fragments (purple bars) containing enhancer
regions (highlighted in gray). 3C interaction with a fragment adjacent to MYC or PVT1 is
used as a reference.
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Summary
In this chapter, we identified MYC and PVT1 as target genes that are being
regulated by the three enhancer regions identified in the previous chapter. These genes
displayed transcription activity at their promoters as indicated byH3K4me3 marks in
ENCODE and FAIRE-seq landscape in our panel of ovarian cells (Table 8).
Additionally, the MYC and PVT1 transcripts were evaluated in our panel of ovarian cells
by RNA-seq analysis. Finally, direct physical interactions between promoter regions of
each of the two genes and enhancer regions in the 8q24.21 ovarian cancer
susceptibility locus confirm MYC and PVT1 as their targets of transcriptional regulation.
An illustration of the proposed interaction is presented in Figure 16.

Table 8. Summary of candidate target genes
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Figure 16. Illustration of looping structure between promoters of target genes and
enhancer regions. Linear chromatin is represented in the top configuration. Looping
structure that brings the enhancer regions and their target genes in close proximity to
each other is represented in the bottom configuration.

Materials and Methods

In Silico Annotation of Candidate Target Genes
The search for candidate target genes extended 1Mb on each side of the 31 Kb
region identified by fine mapping and statistical analysis (totaling approximately 2.03
Mb). We used the USCS Genes prediction track within the Genome Browser
(https://genome.ucsc.edu/) to obtain a comprehensive list of well-annotated human
protein-coding and non-coding genes which comprise our set of candidate target genes.
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Chromosome Conformation Capture (3C) Assay
iFTSEC283 and iOSE11 cells were grown to 80% confluence and cross-linked by
treatment with 1% formaldehyde (Sigma-Aldrich). Cells were subjected to treatment with
homemade lysis buffer (10mMTris HCl pH8, 10mM NaCl, 0.2% NP40 (Sigma-Aldrich)
and 1X protease inhibitor cocktail (Roche). The nuclear extracts were digested with
HindIII (NEB) followed by ligation with T4 DNA Ligase (NEB), which is carried out in
dilute conditions in order to promote intramolecular ligation of the cross-linked
fragments. Ligated and unligated (control) samples were examined on an agarose gel
before proceeding to the next step. The samples were consequently de-cross-linked by
treatment with Proteinase K (Qiagen). The DNA was isolated through phenol-chloroform
extraction and ethanol precipitation prior to quantification by qPCR. The ligated 3C
library was tested using control primers described previously (Lieberman-Aiden et al.,
2009).

Test

primers

were

designed

utilizing

the

Primer

3

online

tool

(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). A list of primers used to
quantify the interactions is included in Table 9. Quantitative PCR of 3C library fragments
was performed as described previously (Tan-Wong et al., 2008). The qPCR reactions
were performed using Hotstart Taq polymerase (Qiagen) and SYTO9 (Life
Technologies) on an ABI 7900HT Real-Time PCR System. Artificial 3C libraries,
obtained from BAC DNA (RPC11-440N18, RP11-55J15, RPCI-11-1142F3 from Empire
Genomics; 2034C18, 96012 from Invitrogen) covering the regions under investigation,
were used to test primer efficiency and to generate standard curves for PCR
quantification of 3C fragments.
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Table 9. 3C Primers used to quantify physical interactions
Primer Name

3F
12F
18F
29R
30R
31R
35R
36R
37R
MYC Bait
MYC Adj
PVT1 Bait
PVT1 Adj

Sequence (5' to 3')

CTAATTATGAGCTGAACGCTTTACG
TGTCATTGTTATGGGAGAATAAAAG
GCTGGGTCCAGTCTGACAAA
GTCACTTGATTCTCCTTTTCCTTTT
CATGAAAACCCTATTAAGCAGAAAA
TAATTCATGTGATTGCATAGTCCAG
TAGCTCAGGAAGATAAACTGAAATG
CCCACCCTCCACTCTAAACC
AGGGTGACAGAGCTTTAGTGAAGTA
GAGAACCGGTAATGGCAAAC
TGCATGGTGTTTCATAGTGAGTT
ATCTTGGAGGTGAGGACGTG
GTCAGGGAGCTGAGGAGTGT

Distance from
Hindiii site (bp)

92
69
81
99
108
50
70
75
45
83
80
45
38
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CHAPTER FOUR:

TRANSCRIPTION FACTOR BINDING ANALYSIS

Note to reader:
A manuscript (Gjyshi et al.) currently under review includes portions of this
chapter.

Introduction
The next step in the analysis of regulatory regions is focused on detection of
potential transcription factor binding sites that are involved in regulation of transcription
of the target genes. We started with an in silico analysis to identify transcription factors
binding sites (TFBS) that are disrupted by SNPs and followed up with experiments to
verify transcription factor binding and specificity.

Results

Prediction of TFBS Disrupted by SNPs
For the 8 SNPs that displayed allele-specific binding in the reporter and EMSA
assays, we used the Match weight matrix-based program (http://www.generegulation.com/cgi-bin/pub/programs/match/bin/match.cgi) to predict transcription factor
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binding sites (TFBS) for the DNA sequences that were used in the EMSA probes
(Table7). A list of predicted transcription factors was generated for each SNP allele.
Interestingly, exclusive binding of Activating Transcription Factor 1 (ATF1) to the minor
allele [C] in the forward orientation) of rs2165806 (region E4; serous p = 1.32 x 10 -19)
was predicted. This predicted binding is completely eliminated upon switching from the
minor [C] to the major [G] allele (Table 10), consistent with EMSA results (Figure 10).

Isolation of ATF1 Transcription Factor Binding rs2165806 by FPLC and
EMSA
To validate this finding experimentally we utilized Fast Protein Liquid
Chromatography (FPLC) combined with EMSA to isolate specific SNP binding proteins
for rs2165806 (Figure 17). Nuclear extracts of 293FT cells were subjected to a first
round of FPLC through a size exclusion column followed by a screen for SNP specific
binding proteins by EMSA. We identified three fractions (fractions 20-22) that displayed
a signal in the EMSA assay. Those fractions were subjected to a second round of FPLC
through an ion-exchange column, followed by EMSA. The two fractions (D4 and D5)
that displayed activity in the second EMSA were separated by electrophoresis and all
six regions (Figure 17; Step 3) were submitted for mass spectrometry analysis. When
proteins matching the gene ontology term “DNA binding” (GO:0003677) were selected,
ATF1 emerged as a significant hit that also had a predicted allele-specific binding
difference in the context of SNP rs2165806 (Table 10). From these experiments we
confirmed ATF1 (Figure 18) to be one of the transcription factors that was isolated from
our DNA probe containing the effect allele [C] for rs2165806. These results were
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confirmed in iOSE4cMYC cells (Figure 19B). This provides evidence that this functional
SNP, harbored within the enhancer region E4, recruits the ATF1 transcription factor in
an allele-specific manner.
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Step 2

Step 1

FPLC (MonoQ)

FPLC (Sepharose)
Fraction 1………………………….……............….36

Fraction 1……………..……….....20

2 Fractions

3 Fractions

Step 3
PAGE

Standard
KD
a25

LC-MS/MS

0
15
0
10
07
5
5
03
7
2
5

D4-5
Region
s
1
2
3
4
5
6

Figure 17. Isolation of ATF1 transcription factor binding to rs2165806 by FPLC
and EMSA. Analysis includes two rounds of FPLC (see supplemental figures) followed
by EMSA screens for SNP specific binding proteins. For the last step, two fractions with
positive EMSA signal were subjected to PAGE and separated into six regions that were
processed for proteomic analysis. Note: FPLC analysis was performed by Nicholas
Woods and the EMSA assay included in this picture was performed by Gustavo
Mendoza.
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Table 10. TFBS predicted by the MATCH program
SNP ID

rs 2165806_ma jorG

rs 2165806_mi norC

Matrix identifier

Position Strand Core match

Matrix
match Sequence (+) strand

Factor name

Present in
minor?

V$OCT1_Q6

1 (-)

0.824

0.709

tga cTTTGGa ca gca

Oct-1

Ye s

V$PAX6_01

3 (-)

0.842

0.577

a ctttgga ca gCATGAa cctc

Pa x-6

Ye s

V$PAX4_01

3 (-)

1

0.711

a ctttgga ca gCATGAa cctc

Pa x-4

Ye s

V$PAX4_01

9 (-)

0.881

0.589

ga ca gca tga a CCTCAgtga a

Pa x-4

Ye s

V$PAX6_01

21 (+)

0.757

0.609

ctca gTGAAGttta tctgga a

Pa x-6

Ye s

V$PAX4_01

21 (+)

0.888

0.66

ctca gTGAAGttta tctgga a

Pa x-4

Ye s

V$FREAC7_01

25 (-)

1

0.861

gtga a gTTTATctgga

Fre a c-7

Ye s

V$GATA_C

27 (-)

1

0.957

ga a gtTTATCt

GATA-X

Ye s

V$GATA1_03

28 (-)

1

0.936

a a gtTTATCtgga a

GATA-1

Ye s

V$LMO2COM_02

30 (-)

1

0.955

gttTATCTg

Lmo2_compl e x

Ye s

V$GATA1_05

30 (-)

1

0.959

gtTTATCtgg

GATA-1

Ye s

V$GATA1_06

30 (-)

1

0.952

gtTTATCtgg

GATA-1

Ye s

V$GATA2_02

30 (-)

1

0.959

gtTTATCtgg

GATA-2

Ye s

Present in
major?

V$OCT1_Q6

1 (-)

0.824

0.709

tga cTTTGGa ca gca

Oct-1

Ye s

V$PAX6_01

3 (-)

0.842

0.577

a ctttgga ca gCATGAa cgtc

Pa x-6

Ye s

V$PAX4_01

3 (-)

1

0.712

a ctttgga ca gCATGAa cgtc

Pa x-4

Ye s

V$PAX4_01

9 (-)

0.879

0.588

ga ca gca tga a CGTCAgtga a

Pa x-4

Ye s

V$ATF_01

14 (-)

1

0.974

catgaaCGTCAgtg

ATF

No

V$CREB_Q2

15 (-)

1

0.903

atgaaCGTCAgt

CREB

No

V$CREBP1_Q2

15 (-)

1

0.873

atgaaCGTCAgt

CRE-BP1

No

V$AP1_Q2

16 (-)

0.967

0.92

tgaaCGTCAgt

AP-1

No

V$AP1_Q4

16 (-)

0.935

0.856

tgaaCGTCAgt

AP-1

No

V$CREB_01

17 (-)

1

0.937

gaaCGTCA

CREB

No

V$CREB_02

17 (-)

1

0.924

gaaCGTCAgtga

CREB

No

V$ER_Q6

17 (-)

0.846

0.792

gaaCGTCAgtgaagtttat

ER

No

V$PAX6_01

21 (+)

0.757

0.609

gtca gTGAAGttta tctgga a

Pa x-6

Ye s

V$PAX4_01

21 (+)

0.888

0.66

gtca gTGAAGttta tctgga a

Pa x-4

Ye s

V$FREAC7_01

25 (-)

1

0.861

gtga a gTTTATctgga

Fre a c-7

Ye s

V$GATA_C

27 (-)

1

0.957

ga a gtTTATCt

GATA-X

Ye s

V$GATA1_03

28 (-)

1

0.936

a a gtTTATCtgga a

GATA-1

Ye s

V$LMO2COM_02

30 (-)

1

0.955

gttTATCTg

Lmo2_compl e x

Ye s

V$GATA1_05

30 (-)

1

0.959

gtTTATCtgg

GATA-1

Ye s

V$GATA1_06

30 (-)

1

0.952

gtTTATCtgg

GATA-1

Ye s

V$GATA2_02

30 (-)

1

0.959

gtTTATCtgg

GATA-2

Ye s
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Figure 18. Proteomics results isolating ATF1 by FPLC and EMSA. A. List of DNA binding proteins screed against
CrapOme (found < 2.5% in CrapOme). ATF1 is marked with a red box. B. 35/271 amino acids were isolated by LCMS/MS (highlighted in yellow). Amino acid affected by rs2165806 is highlighted in green.
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ATF1 Transcription Factor Binds Exclusively to Effect Allele of rs2165806
To confirm ATF1 binding to the rs2165806 site, we performed EMSA super shift
and competition assays with nuclear extracts of 293FT cells. In the competition assays,
the EMSA signal that is detected in the radioactively labeled DNA probe containing the
minor (effect) allele is completely abolished upon competition with unlabeled probe
(Figure 19 A). No signal was detected in the DNA probe containing the major SNP allele
[G]. Furthermore, we incubated nuclear extracts of 293FT and iOSE4cMYC cells
transfected with pNTAP-ATF1, expressing a fusion of Calmodulin-binding protein (CBP)
and ATF1, mixed with anti-CBP antibody and labeled reference or effect allele DNA
probes. We detected a super shift signal in the sample containing the effect allele [C]
probe for rs2165806, but not on the one containing the reference allele [G] probe
(Figure 19 B). This experiment confirms binding of ATF1 to a regulatory element in
region E4 that contains the effect allele of rs2165806.
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A

B

Figure 19. Confirmation of ATF1 binding rs2165806 region. A. ATF1 binding (lane 4,
arrow) is displaced by competition with cold probe containing the Effect allele (lanes 57). Super shift is obtained with the addition of an antibody that recognizes a tag (CBP)
on the ectopic copy of ATF1 (lane 14, upper arrow). B. Replicate EMSA also including
nuclear extracts from iOSE4cMYC cells. ATF1 binding (arrow) and super shift
(arrowhead) are shown.
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To assess the effect of ATF1 on the regulatory region, we co-transfected
iOSE4cMYC cells with a luciferase reporter vector with the rs2165806 region cloned as an
enhancer and an ATF1 expression vector. Ectopic expression of ATF1 increased
expression of a reporter gene driven by a region containing the minor [C] allele of
rs2165806 but not when the reporter is driven by a region with the major [G] allele
(Figure 20). Taken together these experiments indicate that ATF1 binds a region
containing the minor allele of rs2165806 and is able to regulate gene expression.

Figure 20. ATF1 affects transcriptional activity of downstream gene reporter.
Ectopic expression of ATF1 increases expression of a reporter gene driven by a region
containing the effect (minor) [C] allele of rs2165806 but not when the reporter is driven
by a region with the reference (major) [G] allele.
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Homozygous Deletion of ATF1 Binding Region Impacts the Expression of
MYC, PVT1, and TMEM75
To assess the functional relevance of the ATF1 binding region we generated
homozygous deletions by CRISPR-Cas9 in iOSE4CMYC. Clones ΔCC1 and ΔCC2
presented homozygous deletion of the rs2165806 region (Figure 21), while CC3
retained the intact region and was used as a reference. Compared to CC3, a significant
decrease in expression levels were observed for all three genes in the region (MYC,
PVT1, and TMEM75). However, only MYC expression was reduced consistently in both
clones and in both replicates.
To rule out that changes in gene expression were due to large scale
chromosome structural changes due to the CRISPR-mediated deletion we conducted
3C anchoring at MYC or PVT1. Physical interactions between MYC or PVT1 promoters
and regions E3 or E4 in CRISPR clones were similar to the interaction pattern obtained
in unmodified cells (Figure 14 and 15). In summary, deletion of the region containing
SNP rs2165806 led to consistent changes in MYC expression, and in the other two
genes in the region without large effects on chromatin structure.
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A

B

Figure 21. CRISPR-edited clones removing region containing SNP rs2165806.
A. Diagram showing the region removed in two independent iOSE4CMYC CRISPR
clones. Positions of gRNAs used are shown in green boxes. B. RT-qPCR results
depicting the expression of MYC, PVT1, and TMEM75 relative to the expression in a
CRISPR clone with the region intact (CC3). P values are shown (t-test) and nonsignificant values are shown in red font.
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MYC Transcription Factor Binding Sites by ChIP-seq from ENCODE
Furthermore, a search of the ENCODE ChIP-Seq signals for ATF1 also revealed
that this transcription factor as well as BRCA1 have been found to bind to the MYC
promoter (Figure 22). This information opens the possibility of BRCA1 involvement and
also further supports our suggested mechanism of the identified regulatory elements
regulating transcription of distant target genes by recruitment of ATF1.

Figure 22. MYC region illustrating ChIP-Seq signals for BRCA1 (in HeLa cells) and
for ATF1 (in K562 cells); SYDH TFBS (Transcription Factor Binding Sites by ChIP-seq
from ENCODE/Stanford/Yale/USC/Harvard) available through the human genome
browser as part of ENCODE.

91

Summary
In this chapter we identified and validated specific and exclusive binding of the
ATF1 transcription factor to the enhancer region (E4) containing the effect allele [C] of
the rs2165806 SNP. The predicted ATF1 binding to this region was confirmed by mass
spectrometry and further validated by EMSA competition and super shift assays. ATF1
binding to the E4 enhancer region was also shown to regulate gene expression as
demonstrated by luciferase assays. Furthermore, deletion of the ATF1 binding region by
CRISPR-Cas9 mediated genome editing resulted in decreased levels of gene
expression of MYC, PVT1 and TMEM75. Additional evidence of ATF1 and BRCA1
binding at the promoter region of MYC in two cell lines suggests possible involvement of
BRCA1 in transcriptional regulation of MYC.

Materials and Methods

Fast Protein Liquid Chromatography (FPLC) Coupled with EMSA

Note to reader: FPLC was performed by Nicholas Woods.

We started with Dignam-based nuclear extracts of 293FT cells (Dignam et al.,
1983). Nuclear extracts (10mg) were loaded onto FPLC using size exclusion column
Sepharose 6 10/300 GL, and fractions were screened for SNP-specific binding proteins
by EMSA. Fractions displaying EMSA signals were combined and subjected to buffer
exchange and concentration. Samples were then subjected to a second round of FPLC
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using ion-exchange column MonoQ 5/10 GL. These fractions were again screened by
EMSA. The two fractions displaying EMSA signals were combined and concentrated
and then subjected to polyacrylamide gel electrophoresis (PAGE). The gel was
separated into six regions, processed for in-gel trypsin digestion, and submitted to the
Moffitt Proteomics core for mass spectrometry analysis on the Orbitrap instrument.

EMSA Competition and Super Shift Assays
EMSA samples were prepared as described in Chapter 2. For the competition
assays a cold (unlabeled) probe was used in addition to the labeled probe containing
the effect allele [C] for rs2165806. The super shift assay was performed with cells
overexpressing ATF1 fused to CBP and CBP antibody was added to the reaction.

CRISPR-Cas9 Mediated Genome Editing in iOSE4cMYC Cells
We used the CRISPR (clustered regularly interspaced short palindromic
repeats)-Cas9 system to remove the region containing the ATF1 binding site, which
includes rs2165806, in iOSE4CMYC cells, as previously described (Storici, 2014). Briefly,
six gRNA sequences (Table 11) were designed and cloned into the gRNA cloning
vector (Addgene, plasmid ID 41824) following the Mali lab protocol option B
(http://arep.med.harvard.edu/human_crispr/).

Incorporation of gRNA sequences was

confirmed by Sanger sequencing using the M13 Reverse universal sequencing primer.
iOSE4CMYC cells were co-transfected with six gRNA expression constructs or the empty
gRNA plasmid and hCas9 (Addgene, plasmid ID 41815) and pBABE-puro (Addgene,
plasmid ID 1764) using FugeneHD transfection reagent (Promega, E2311) at a 3:1 ratio
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of FugeneHD volume (µL) to DNA (µg). Forty eight hours post transfection, cells were
harvested, plated at different densities, and treated with 1 µg/mL puromycin. Individual
clones were isolated and expanded in cell culture. Excision of the AFT1 binding site was
confirmed by sequencing (Table 11). Two clones (ΔCC1 and ΔCC2) were confirmed to
have the desired CRISPR-mediated deletions at Chr8:129,569,456-129,569,629 and
Chr8:129,569,456-129,569,618. One CRISPR clone presented with a small deletion
(Chr8:129,569,577-129,569,618) but with the ATF1 binding region intact (CC1) and was
retained as a negative control.

Table 11. gRNA and sequencing primers used in CRISPR experiments
Oligos

Primer Name

Sequence (5' to 3')

gRNA1

rs216Guide3Fwd

TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTTCTCAAAACAAGTTTGCC

gRNA1

rs216Guide3Rev

GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGGCAAACTTGTTTTGAGAAC

gRNA2

rs216Guide4Fwd

TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTTTGCCAGGCAAGTATTAT

gRNA2

rs216Guide4Rev

GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACATAATACTTGCCTGGCAAAC

gRNA3

rs216Guide5Fwd

TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAACCTCAGTGAAGTTTATC

gRNA3

rs216Guide5Rev

GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGATAAACTTCACTGAGGTTC

gRNA4

rs216Guide6Fwd

TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTCCAAAGTCACACAGCGCT

gRNA4

rs216Guide6Rev

GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACAGCGCTGTGTGACTTTGGAC

gRNA5

rs216Guide7Fwd

TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGTCCAAAGTCACACAGCGC

gRNA5

rs216Guide7Rev

GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGCGCTGTGTGACTTTGGACC

gRNA6

rs216Guide8Fwd

TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGTAGGTGTGCAGTAATGCAT

gRNA6
Sequencing
primer F
Sequencing
primer R

rs216Guide8Rev

GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACATGCATTACTGCACACCTAC

CRISPRfwd

TGGTCCCACTACATACCTAGCA

CRISPRrev

GAGAGCCTGGCACAAAGTAAG

Gene Expression
RNA from CRISPR clones was extracted using the Qiagen RNeasy Mini-Prep Kit
and reverse transcription was performed using the Qiagen QuantiTect Reverse
Transcription Kit per manufacturer’s specifications. Quantitative PCR was performed
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using TaqMan gene expression assays for MYC (Hs00153408_m1), PVT1
(Hs00413039_m1) and TMEM75 (Hs02597353_s1). Eukaryotic 18S rRNA assay was
used as internal control (Thermo Fisher, 4319413E). The delta-delta method was used
to determine levels of expression compared to the negative CRISPR clone in two
biological replicates.
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DISCUSSION AND FUTURE WORK

We present a comprehensive fine mapping and functional analysis of the
8q24.21 ovarian cancer locus to identify biological mechanisms underlying disease
susceptibility. Fine-mapping revealed rs1400482 to have the most significant
association with ovarian cancer (p = 2.5x10-13), especially with the serous subtype (p =
1.9 x10-20). Log likelihood statistics identified 52 SNPs with odds of 100:1 or better of
being true causal variants narrowing down the signal of association from a ~500 kb to a
~31 kb region. Three additional independent signals were found, including rs4524749
located proximal to MYC and rs74559819 located inside the PVT1 region, and
rs2165805 which reached genome-wide significance for association with clear cell
ovarian cancer.
For the most significant association, overlaying chromatin features data identified
eight functional SNPs (Table 3, Figure 5) that are in strong LD (r² = 1) with each other
as well as the most highly associated SNP from fine-mapping (rs1400482) and the initial
tagSNP (rs10088218). The identified SNPs mark two regulatory regions (E2 and E4)
that modulate transcription of MYC and/or PVT1 genes via, at least partially, the
recruitment of the ATF1 transcription factor (Figure 23).
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Figure 23. Summary of functional analyses of ovarian cancer susceptibility at the
8q24 locus. Rules guiding SNP selection and prioritization of causal SNPs. The study
identified two enhancer regions with 8 causal SNPs that interact with MYC and, to a
lesser extent, PVT1 promoter regions.

The decreased risk haplotype (defined by [A] allele of rs10088218) contains the
ATF1 binding site (rs2165806 effect allele, which is [C] in forward orientation)
suggesting that the absence of binding of ATF1 leads to deregulated higher MYC
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expression. This is consistent with enhancer scanning data in which a tile with the [C]
allele shows decreased activity when compared to the major [G] allele (Figure 5D).
Plausibly, a relatively higher basal level of MYC expression could lead to oncogenesis.
Several lines of evidence support the notion that deregulation of MYC and PVT1
lead to ovarian oncogenesis. MYC is a transcription factor known to play a central role
in carcinogenesis (Hermeking et al., 2000) and can cooperate with other somatic
alterations to transform ovarian and fallopian cells when ectopically overexpressed
(Lawrenson et al., 2010; Xing and Orsulic, 2006). Although MYC is tightly regulated and
subtle changes in its protein levels may not be detectable by experimental approaches,
it is possible that even a slight fluctuation in its protein levels may have a major impact
on various cellular processes (Li et al., 2003). Interestingly, MYC may be regulated
through a positive feedback type of interaction wherein MYC activates transcription of
PVT1, which in turn promotes stability of the MYC protein (Carramusa et al., 2007;
Tseng et al., 2014). Of note, conditional analysis revealed an independent peak of
association that was not correlated with the top SNP but located proximal to the MYC
promoter and inside the PVT1 region (Figure 6).
Over-expression or amplification of MYC occurs in up to 65% of EOCs (Chen et
al., 2005; Wisman et al., 2003), and amplification of 8q24 (including MYC and PVT1)
has been found to be correlated with poorer survival in 380 stage I to III ovarian tumors
when compared to patients with tumors without 8q24 amplification (Guan et al., 2007).
The region commonly shows focal amplification in high grade serous tumors (Cancer
Genome Atlas Research, 2011). In addition to correlative studies, in vitro models of
ovarian cancer progression also support a role for MYC and PVT1 in ovarian cancer.
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Immortalized ovarian cells transformed with MYC show expression signatures strongly
correlated with those of invasive high-grade, but not low malignant potential, EOCs
(Lawrenson et al., 2011). Also, siRNA-mediated silencing of PVT1 expression has been
seen to result in decreased cell proliferation and increased apoptosis in breast and
ovarian cancer cell lines, an effect restricted to cells in which PVT1 was amplified (Guan
et al., 2007).
Although ATF1 has been reported to interact with and to be co-activated by
BRCA1 (Houvras et al., 2000) a direct role for ATF1 in ovarian cancer has not been
previously reported. Interestingly, inspection of the MYC region for ENCODE data for
BRCA1 and ATF1 ChIP-Seq revealed a peak of BRCA1 binding in HeLa cells which
overlaps with ATF1 binding in K562 cells (the only cell line with data for ATF1 binding)
(Figure 22), raising the possibility of BRCA1 involvement.
This locus has also been associated with several other traits at genome-wide
significance levels. In particular, the cluster of functional SNPs identified contains a SNP
that has been associated with increased risk of two chronic inflammatory diseases,
rheumatoid arthritis (rs1516971) (Okada et al., 2014) and Crohn’s disease (rs6651252)
(Franke et al., 2010). Rs6651252 is contained in Region E3 which showed significant
interactions with the promoter of MYC but the SNP failed to show allele-specific activity
in ovarian cells (Table 3). Given previously reported associations between inflammation
and ovarian cancer risk (Charbonneau et al., 2013; Risch and Howe, 1995) further
dissection of these interactions is warranted.
In terms of clinical implications of our findings, further work is needed to evaluate
the cumulative effects of common genetic variants in development of disease. We are
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just beginning to unveil the mechanisms by which these variants could influence
disease. At this stage, given their small genetic effect, genetic testing would not be
recommended due to our uncertainty in interpreting the results of such testing. Another
possibility is to consider MYC and/or PVT1 as therapeutic targets for cancer patients.
Myc particularly is an attractive therapeutic target because it is implicated in a wide
variety of human cancers, and drugs that specifically target Myc could, therefore, have
an impact in the treatment of a broad range of malignancies. There are several
strategies that can be explored to inactivate expression or function of Myc at different
biological

levels

by

utilizing

various

novel

approaches

such

as

antisense

oligonucleotides, siRNA, or small molecule inhibitors, which can be employed alone or
in combination with current therapies. However, there are several challenges that limit
the application of these approaches including the stability/degradation of these
compounds under physiological conditions, delivery methods and uptake by target cell
population, drug-related toxicity and resistance, possible side effects, etc. There is
tremendous potential that remains to be explored toward clinical applications of these
findings, and it is likely that successful interventions will combine attacks at multiple
levels to achieve long-term success.
A particular strength of this project is the very large sample size that provided
ample power to identify risk associations and to prioritize the most likely causal SNPs
for functional analysis. Limitations of this work include the use of data derived from cell
lines and from non-chromatinized assays that may not represent the tissue and cell
nuclear environments of the cells from which ovarian neoplasms originate. The use of a
panel of normal ovarian and cancer cell lines, multiple functional assays, and the
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integration of publically available data reduces those limitations and provides a
framework for more in-depth functional analyses. Our data implicate MYC as the nexus
of a regulatory network in the 8q24.21 locus that drives susceptibility to many cancers
including ovarian cancer. Further analysis will be necessary to understand the general
and cell type-specific pleiotropic contributions of individual enhancer elements to risk of
ovarian and other cancers and to other diseases.
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During my time in the Ph.D. program, in addition to this dissertation, I worked on
numerous other projects that resulted in publications and poster presentations as
follows:
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Gjyshi A, Dash, S, Cen L, Cheng CH, Zhang C, Yoder SJ, Teer J, Armaiz-Pena
GN, Monteiro AN (2018) Early transcriptional response of human ovarian and
fallopian tube surface epithelial cells to norepinephrine. Scientific Reports
8(1):8291.

As a lead author, I contributed to the above referenced paper by developing and
implementing ideas; performing RNA-isolation, gene expression assays and western
blot experiments; interpreting results; literature curation and manuscript preparation.
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Teer JK, Yoder S, Gjyshi A, Nicosia SV, Zhang C, Monteiro AN (2017) Mutational
heterogeneity in non-serous ovarian cancers. Scientific Reports 7(1):9728.

As a contributing author, I performed literature curation and compiled a comprehensive
overview of the current published knowledge on somatic alterations and germline
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variation in high grade serous ovarian cancer, which is found in Supplementary Table 1.
I also participated in data analyses and manuscript preparation.
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Buckley MA, Woods NT, Tyrer J, Mendoza-Fandino G, Lawrenson K, Hazelett DJ.,
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9p22.2 ovarian cancer susceptibility locus reveals a transcription regulatory
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Figure 2B, Figure 3H and Supplementary Table 1.
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ideas, resource building, designing workflow, primer design, tile generation, cloning,
mutagenesis, creating BED files and custom tracks, performing luciferase reporter
assays, troubleshooting, generating Figure 4 and Figure 5, and manuscript preparation.
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GWAS meta-analysis and replication identifies three new susceptibility loci for
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Communications, revised manuscript in preparation).
This is my main project during my doctoral training and my contribution is discussed in
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